The QualityStocks Daily Monday, January 9th, 2023

Today's Top 3 Investment Newsletters

MarketClub Analysis(AMYT) $14.5100 +107.29%

QualityStocks(GMVD) $4.4000 +52.78%

Schaeffer's(DCT) $19.0300 +46.50%

The QualityStocks Daily Stock List

G Medical Innovations (GMVD)

QualityStocks, MarketClub Analysis and RedChip reported earlier on G Medical Innovations (GMVD), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

G Medical Innovations Holdings Ltd (NASDAQ: GMVD) (FRA: 9GMO) is a commercial stage healthcare firm that is focused on developing next generation mobile health and telemedicine solutions.

The firm has its headquarters in Rehovot, Israel and was incorporated in August 2014. It serves consumers in Israel, China and the United States.

The company provides consumer and clinical grade products which help decrease inefficiencies in healthcare delivery, improve quality of care, decrease costs, enhance access and make healthcare more precise and personalized. It operates through the products and services segments. The services segment includes cardiac monitoring services of Pacemaker, Extended Holter, Event, Patch and MCT. On the other hand, the products segment is involved in developing, manufacturing and marketing transphonic and wireless diagnostic equipment for the consumer markets and the medical industry.

The enterprise’s products include a solution which offers real-time monitoring of biometrics and vital signs, known as the Wireless Vital Signs Monitoring System. It also develops a multi-channel biosensor dubbed the Extended Holter Patch system, which collects electrocardiogram data for up to 2 weeks; and a plug-and-play medical device which measures an individual’s vital signs and has clinical grade reporting standards, known as Prizma. In addition to this, the enterprise provides monitoring services, which include private and independent diagnostic testing facility monitoring services.

The firm recently announced its latest financial results, which show significant increases in revenues and improvement in the demand for its services. It is currently focused on its growth strategy, which involves the expansion of its cardiac service monitoring opportunities with healthcare providers.

G Medical Innovations (GMVD), closed Monday's trading session at $4.4, up 52.7778%, on 12,823,733 volume. The average volume for the last 3 months is 1.362M and the stock's 52-week low/high is $1.94/$235.8965.

Titan Medical (TMDI)

StockMarketWatch, MarketBeat, QualityStocks and TradersPro reported earlier on Titan Medical (TMDI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Titan Medical Inc. (NASDAQ: TMDI) (TSE: TMD) (FRA: QTNA) is a research and development stage firm that is engaged in the designing, developing and commercializing robotic surgical technologies used in minimally invasive surgeries.

The firm has its headquarters in Toronto, Canada and was incorporated in 2008 on July 28th. It operates as part of the physicians’ industry in the healthcare sector, under the medical equipment and devices sub-industry.

The company’s objective is to improve robotic assisted surgery through technology that needs only one patient access site, which allows patients to recover faster and also reduces patient scarring and trauma. Its objectives are to help decrease operating room costs, enhance patient outcomes and design technology that is both easy to use and effective, which allows physicians to perform their best.

The enterprise’s portfolio is made up of the Enos system, which is a single-port robotic surgical system which integrates a surgeon workstation that offers the surgeon a 3D endoscopic view into the patient’s body during surgery and an ergonomic interface to the patient cart; multi-articulating instruments and 3D high definition vision system used to perform minimally invasive procedures. The instruments have replaceable tips. This SPORT surgical system allows surgeons to perform surgical procedures for bariatric, colorectal, urologic and gynecologic conditions. Additionally, this system represents the company’s holistic approach to development.

The company recently appointed a new vice president who will oversee its strategic planning and development. The new appointee has vast knowledge and experience in strategic partnerships and business development which will be valuable in helping the company grow. Boosting the company’s growth will encourage more investments into the firm, which will be beneficial to its stakeholders.

Titan Medical (TMDI), closed Monday's trading session at $0.93, up 22.0953%, on 1,364,453 volume. The average volume for the last 3 months is 105,780 and the stock's 52-week low/high is $0.38/$0.9764.

Travelzoo (TZOO)

The Street, All about trends, TopStockAnalysts, Zacks, Greenbackers, MarketBeat, SmarTrend Newsletters, InvestorPlace, TradersPro, Marketbeat.com, StreetInsider, Trading Concepts, Investor Update, Stockhouse, StreetAuthority Daily, StockMarketWatch, Money Morning, Investment U, FeedBlitz, Profit Confidential, Dynamic Wealth Report, Daily Trade Alert, WStreet Market Commentary, Investopedia, Daily Wealth, Daily Gains Letter, BUYINS.NET, Market Authority, Forbes, MarketClub Analysis, Momentum Traders, PoliticsAndMyPortfolio, SmallCapNetwork, smartOTC, Stock Traders Chat, Stocks That Move, Stocktwiter, StockTwits, Street Insider, Trades Of The Day, Trading Markets, Uncommon Wisdom, Wealthpire Inc. and ShazamStocks reported earlier on Travelzoo (TZOO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Travelzoo (NASDAQ: TZOO) (FRA: TXM1) is an internet media firm that is engaged in the provision of travel, entertainment and local deals from entertainment and travel firms as well as local businesses.

The firm has its headquarters in New York and was incorporated in 1998 on May 21st by Ralph Bartel. It operates as part of the advertising agencies industry, under the communication services sector. The firm serves consumers in the North America, the Asia Pacific and Europe.

The company's segments include Travelzoo Europe, Travelzoo North America and Jack's Flight Club. Travelzoo Europe comprises of its operations in Germany, France, Spain, and the United Kingdom while Travelzoo North America comprises of its operations in the United States and Canada. On the other hand, Jack's Flight Club comprises of subscription revenue from premium members to access and receive flight deals from Jack's Flight Club via Android or Apple mobile applications or through email.

The enterprise’s publications and products include Travelzoo iPhone and Android apps; Travelzoo Website; Travelzoo Top 20 email newsletter; and Newsflash email alert service. It also operates the Travelzoo Network, a network of third-party websites that list travel deals published by the company; and Local Deals and Getaway listings, which allow its members to purchase vouchers for deals from local businesses, such as hotels, restaurants and spas. It serves hotels, airlines, car rental firms, cruise lines, tour operators, restaurants, vacations packagers, spas, destinations, theater and performing arts groups, travel agents and activity companies.

The firm’s latest financial results show increases in its revenues, with its CEO noting that they remained focused on accelerating revenue growth. This will help create shareholder value while also bolstering the firm’s growth.

Travelzoo (TZOO), closed Monday's trading session at $4.96, off by 0.201207%, on 106,266 volume. The average volume for the last 3 months is 20,990 and the stock's 52-week low/high is $4.10/$10.28.

Koss Corporation (KOSS)

InvestorPlace, MarketClub Analysis, TradersPro, MarketBeat, QualityStocks, The Street, StreetInsider, Investopedia, Penny Stocks VIP, BUYINS.NET, Daily Stock Motion, Gryphon Digest, NYSE Post, WINNINGOTC, The Online Investor, Wall Street Wolves, StockMarketWatch, Wall Street Resources, Street Insider, Wall Street Beauties, The Bull Report, Value Penny Stocks, Equity Observer, FatCat Stocks, Greenbackers, Growing Stocks Reports, HotStockProfits, INO Market Report, Trades Of The Day, Penny Pick Insider, Market FN, SMS Penny Picks, Marketbeat.com, MarketWatch, Michael Stone, Actual Gains, The Best Newsletters, PennyStockRumors.net, PricelessPennyStocks, Research Driven Investor and Kiplinger Today reported earlier on Koss Corporation (KOSS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Koss Corporation (NASDAQ: KOSS) is a company focused on designing, manufacturing and selling stereo headphones and related accessories.

The firm has its headquarters in Milwaukee, Wisconsin and was incorporated in 1958 by John C. Koss Sr. It operates as part of the consumer electronics industry, under the technology sector. The firm serves consumers around the globe, with a focus on those in the United States, Canada, Sweden, the Czech Republic, Malaysia, Ukraine and the Russian Federation.

The company operates in the audio/video industry segment of the home entertainment industry. It generates most of its revenue from the sale of stereo headphones. The company’s subsidiaries include Koss U.K. Limited and Koss Corp B.V.

The enterprise provides high-fidelity headphones, wireless Bluetooth speakers, wireless Bluetooth headphones, active noise canceling headphones, computer headsets and telecommunications headsets. It also sells a range of utility series accessories. It sells its products through international distributors, local distributors, the internet, audio specialty stores, military exchanges, national retailers, electronics retailers, grocery stores and prisons under the Koss name, as well as private label. It also sells its products directly to other manufacturers as well as to distributors for resale to school systems. As of June 2022, the enterprise had approximately 90 domestic dealers; and roughly 2,000 domestic retail outlets and numerous retailers.

The firm, which recently announced its latest financial results, remains focused on revenue growth. This will help create shareholder value while also bolstering the firm’s overall growth.

Koss Corporation (KOSS), closed Monday's trading session at $5.405, up 2.5617%, on 21,140 volume. The average volume for the last 3 months is 12,200 and the stock's 52-week low/high is $4.441/$12.86.

DallasNews Corp. (DALN)

The Online Investor reported earlier on DallasNews Corp. (DALN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

DallasNews Corp. (NASDAQ: DALN) is a local news and information publishing firm that operates and owns commercial printing, distribution and direct mail service businesses.

The firm has its headquarters in Dallas, Texas and was incorporated in 1842. Prior to its name change in June 2021, the firm was known as A.H. Belo Corporation. It operates as part of the publishing industry, under the communication services sector. The firm serves consumers in the United States, with a focus on those in Texas.

The company operates through the Publishing and Marketing segments. The Publishing segment includes the operations of The Dallas Morning News and different niche publications targeting specific audiences. The Marketing segment focuses on the marketing services generated by DMV Holdings and its subsidiaries; MarketingFX, Vertical Nerve and Distribion.

The enterprise publishes a newspaper known as The Dallas Morning News; a newspaper known as Briefing; and a Spanish-language newspaper known as Al Dia. It also provides commercial printing, direct mail, distribution, and shared mail packaging services. In addition, it operates a full-service agency dubbed Medium Giant; offers digital marketing services, such as multi-channel marketing solutions through subscription sales of its cloud-based software; digital and marketing analytics, search engine marketing, and other marketing related services; social media account management and content marketing services; and multi- channel digital advertising and marketing services campaigns.

The company, which recently announced its latest financial results, remains focused on building a sustainable profitable digital business. This will not only generate additional revenues for the company but also bolster its overall growth.

DallasNews Corp. (DALN), closed Monday's trading session at $4.25, off by 1.1605%, on 12,254 volume. The average volume for the last 3 months is 179,118 and the stock's 52-week low/high is $3.73/$8.49.

XWELL Inc. (XWEL)

We reported earlier on XWELL Inc. (XWEL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

XWELL Inc. (NASDAQ: XWEL) (FRA: V9G) is a health and wellness services firm that is engaged in the provision of spa services at airports globally.

The firm has its headquarters in New York and was incorporated in 2006, on January 9th by David Goldfarb and Jonathan Medved. Prior to its name change in October 2022, the firm was known as XpresSpa Group Inc. It operates as part of the personal services industry, under the consumer cyclical sector. The firm serves consumers in the United States, the United Arab Emirates and Holland.

The company operates through the XpresSpa, Treat, XpresTest and HyperPointe segments. The XpresSpa segment offers travelers premium spa services, including massage, nail and skin care, as well as spa and travel products while the Treat segment comprises of access to integrated care designed to deliver on-demand access to integrated healthcare through technology and personalized services. On the other hand, the XpresTest segment deals with diagnostic COVID-19 tests at XpresCheck Wellness Centers in airports, to airport employees and to the traveling public. HyperPointe is a digital healthcare and data analytics relationship firm serving the global healthcare industry.

The enterprise’s spa services include massage, and nail and skin care, as well as spa and travel products; and retail products. As of December 2021, it operated 52 spa and clinic locations in 24 airports in the Netherlands, the United States and the United Arab Emirates.

The company has partnered with Human Touch and HydroMassage manufacturers to introduce fully customizable and autonomous services in select locations in the U.S. This move will not only extend the company’s reach but also open it up to new growth and investment opportunities.

XWELL Inc. (XWEL), closed Monday's trading session at $0.434, up 6.0347%, on 179,598 volume. The average volume for the last 3 months is 45,138 and the stock's 52-week low/high is $0.31/$1.88.

Onfolio Holdings (ONFO)

We reported earlier on Onfolio Holdings (ONFO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Onfolio Holdings Inc. (NASDAQ: ONFO) is a diversified holding firm that is focused on the acquisition and development of internet businesses.

The firm has its headquarters in Wilmington, Delaware and was incorporated in 2020, on July 20th by Dominic Wells. It operates as part of the internet content and information industry, under the communication services sector. The firm serves consumers in the United States.

The company acquires controlling interests in and actively manages small websites with a focus on useful content. It operates through its wholly-owned subsidiaries, which include Onfolio LLC, Mighty Deals LLC, Vital Reaction LLC, Inner Studios LLC, Onfolio Gaming LLC, Onfolio Crafts LLC and SEOButler Inc.

The enterprise focuses on website management, advertising and content placement on its websites, and product sales. It provides 2 plugins that focus on file and password protection for WordPress sites, which are Prevent Direct Access (PDA) and Password Protect WordPress (PPWP). It also acquires and manages a diversified portfolio of its online businesses across a range of verticals, such as arts and crafts, pets, business-to-business (B2B) search engine optimization (SEO) services, computers, molecular hydrogen supplements, graphic design, and people search.

The company, which recently provided a corporate update following its acquisition of BWPS, remains focused on advancing its strategy to acquire and manage a diversified portfolio of online businesses. This will deliver long-term growth and open the company up to new investment opportunities while also creating value for its shareholders.

Onfolio Holdings (ONFO), closed Monday's trading session at $1.75, up 5.4217%, on 45,151 volume. The average volume for the last 3 months is 21,826 and the stock's 52-week low/high is $1.05/$3.66.

AmeriCann Inc. (ACAN)

QualityStocks, InvestorPlace, Promotion Stock Secrets, TopPennyStockMovers, Wall Street Mover, TheMicrocapNews, SmallCapVoice, Real Pennies, OTC Markets Group, MarketBeat and Cannabis Financial Network News reported earlier on AmeriCann Inc. (ACAN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

AmeriCann (OTCQB: ACAN), a cannabis company that develops state-of-the-art cultivation, product manufacturing and distribution facilities, today released financial and operational results for its fiscal year and quarter ending September 2022. “Our focus on cost efficiency has produced some of the strongest adjusted operating EBITDA margins in the industry,” said CFO Ben Barton. “We look forward to investing the cash flow we are generating to further expand operations at the Massachusetts Cannabis Center and to produce even better financial results for shareholders.”

To view the full press release, visit https://ibn.fm/hmtzw

About AmeriCann Inc.

AmeriCann is a cannabis company that develops cultivation, processing and product manufacturing facilities. AmeriCann uses greenhouse technology, which is superior to the current industry standard of growing cannabis in warehouse facilities under artificial lights. According to industry experts, by capturing natural sunlight, greenhouses use 25% fewer lights, and utility bills are reduced by as much as 75% compared to typical warehouse cultivation facilities. As such, AmeriCann’s Cannopy System enables cannabis to be produced with a greatly reduced carbon footprint, making the final product less expensive. Additionally, greenhouse construction costs are nearly half of warehouse construction costs. AmeriCann is also designing GMP Certified cannabis extraction and product manufacturing infrastructure. The company has secured provisional licenses to produce cannabis-infused products including beverages, edibles, topicals and concentrates. AmeriCann plans to operate a marijuana product manufacturing business at the Massachusetts Cannabis Center. For more information about the company, visit www.AmeriCann.co.

AmeriCann Inc. (ACAN), closed Monday's trading session at $0.139, up 21.8764%, on 21,829 volume. The average volume for the last 3 months is 87,413 and the stock's 52-week low/high is $0.08/$0.755.

FSD Pharma Inc. (HUGE)

QualityStocks, Schaeffer's, BUYINS.NET, StockMarketWatch, MarketClub Analysis, Penny Dreamers, InvestorPlace, CFN Media Group and AwesomeStocks reported earlier on FSD Pharma Inc. (HUGE), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announced the incorporation of a new subsidiary to capitalize on drug development incentives in Australia. The company also announced its expanded focus to investigate other products addressing acute medical needs due to substances of abuse such as alcohol, as well as the appointments of Dr. Jeremy Chataway, Dr.Ashwin Dhanda and Dr. Anh Lê to its scientific and clinical expert committee. “We are excited about the incorporation of FSD Pharma Australia, where we have an excellent opportunity to advance our pipeline,” said FSD Pharma President Zeeshan Saeed of the company’s recently established subsidiary to facilitate its development of Lucid-Psych (Lucid-201) and potentially other assets. “Australia is a hotbed for clinical stage biotech companies, and our drug development programs will be able to take advantage of facilities offered by various government incentives in Australia.”

To view the full press release, visit https://ibn.fm/dp71G

About FSD Pharma Inc.

FSD Pharma is a biotechnology company with three drug candidates in different stages of development. FSD BioSciences Inc., a wholly owned subsidiary, is focused on pharmaceutical research and development of its lead compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases. Lucid Psycheceuticals Inc., a wholly owned subsidiary, is focused on the research and development of its lead compounds, Lucid-Psych and Lucid-MS. Lucid-Psych is a molecular compound identified for the potential treatment of mental health disorders, and expanding this category, the company is investigating other products addressing acute medical needs due to drugs of abuse such as alcohol. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders. For more information, visit the company’s website at www.FSDPharma.com.

FSD Pharma Inc. (HUGE), closed Monday's trading session at $0.8433, up 2.8415%, on 87,773 volume. The average volume for the last 3 months is 3.384M and the stock's 52-week low/high is $0.6181/$1.11.

atai Life Sciences N.V. (ATAI)

QualityStocks, MarketBeat, The Online Investor, StockMarketWatch, StreetInsider, Dynamic Wealth Report, Uncommon Wisdom, Marketbeat.com, MarketClub Analysis, CRWEFinance, CRWEPicks, CRWEWallStreet, DrStockPick, PennyOmega, BestOtc, Schaeffer's, StockHotTips, TraderPower, PennyToBuck, StockOodles, Street Insider, The Street and TopPennyStockMovers reported earlier on atai Life Sciences N.V. (ATAI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

New research has found that the intensity of a psilocybin trip doesn’t depend on an individual’s body mass index (BMI). BMI is a measure of body fat based on height and weight that applies to adults. Psilocybin is the primary psychoactive compound found in hallucinogenic mushrooms. When ingested, this compound acts as a receptor agonist of 5-HT2A to activate serotonin receptors in the prefrontal cortex in the brain. This decreases the energy required by the brain to alternate between different activity states.

A Center for Psychedelic Research research associate, Meg J. Spriggs, the author of the study, stated that the objective of the research was to find out if an adjustment based on body weight was necessary in the administration of psilocybin during therapy. For their study, the researchers at Imperial College London tested whether the outcome of an individual’s psychedelic experience was impacted by their BMI when a 25 mg dose was administered.

The group conducted an analysis of data from three separate studies involving 77 participants in total, with the average participant age being 43. One of the studies examined long-term brain and psychological changes in individuals who had never consumed a psychedelic while the remaining two studies focused  on the possible use of psilocybin in the treatment of depression.

The investigators measured the BMI of every participant to find out whether they were normal weight, underweight or overweight. Each participant was also required to complete an evaluation of the altered states of consciousness associated with the state they experienced after psilocybin was administered.

The researchers determined that body weight adjusted dosing was not needed, as a fixed dose for all individuals was adequate in inducing an acute experience. They also found that while emotional breakthroughs and otherworldly experiences were powerful predictors of improvements in a participant’s well-being, their body mass index was not. Overall, the results demonstrated that the intensity of the experience was uninfluenced by differences in the BMI of the participants.

In the report, Spriggs highlighted that body weight adjusted vs. fixed dosing had implications for clinical applications in studies where the body mass index was part of the diagnostic criteria, such as in anorexia.

The researchers’ findings were reported in the “Journal of Psychopharmacology.” Other researchers involved include Bruna Giribaldi, Laura S. Kärtner, Fernando E. Rosas, Taylor Lyons, David J. Nutt, Hannah M. Douglass, Tobias Buchborn, Leor Roseman, David Erritzoe, Christopher Timmermann and Robin L. Carhart-Harris.

It should be noted that psilocybin is still classified as a Schedule I drug by the Drug Enforcement Administration, which makes it illegal in the United States.

Plenty of research on psychedelics is currently being undertaken by several startups, such as atai Life Sciences N.V. (NASDAQ: ATAI). The findings are sure to expand the scientific data available on the medical potential of several of these substances.

atai Life Sciences N.V. (ATAI), closed Monday's trading session at $1.65, off by 9.3407%, on 3,388,407 volume. The average volume for the last 3 months is 7.159M and the stock's 52-week low/high is $1.45/$7.02.

Newmont Corporation (NEM)

MarketClub Analysis, InvestorPlace, The Street, Kiplinger Today, Schaeffer's, StocksEarning, INO.com Market Report, The Online Investor, MarketBeat, Barchart, StreetAuthority Daily, Daily Trade Alert, TopStockAnalysts, StreetInsider, Top Pros' Top Picks, Louis Navellier, Streetwise Reports, Daily Wealth, SmarTrend Newsletters, Zacks, Investopedia, Uncommon Wisdom, TradingMarkets, Money Morning, Marketbeat.com, PROFIT CONFIDENTIAL, The Growth Stock Wire, Wealth Daily, Trades Of The Day, TheStockAdvisor, The Wealth Report, Lebed.biz, ProfitableTrading, Wall Street Grand, QualityStocks, Cabot Wealth, Investing Signal, Market Intelligence Center Alert, TheStockAdvisors, The Best Newsletters, Dividend Opportunities, All about trends, National Inflation Association, Trading Markets, InvestmentHouse, Energy and Capital, Market FN, Wyatt Investment Research, Money and Markets, AllPennyStocks, Darwin Investing Network, Stockhouse, TradingAuthority Daily, Buttonwood Research, Daily Markets, Wall Street Daily, InvestorsObserver Team, Street Insider, OTC Stock Pick, The Tycoon Report, Investors Alley, Trading Tips, StreetAlerts, Wall Street Greek, Investiv, Dynamic Wealth Report, MarketWatch, Investing Futures, Trader Jack, Wealth Insider Alert, Market Authority, Short Term Wealth, StockTwits, Investment House, Trading Concepts, FNNO Newsletters, Investment U, FutureMoneyTrends.com, Daily Profit, 24/7 Trader and The Stock Enthusiast reported earlier on Newmont Corporation (NEM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Despite a relatively volatile performance in 2022 coupled with a two-year low in September, gold prices recovered and were trending upward as the year drew to a close. After gold prices went down to $1,659.47 per ounce in mid-September, the lowest they had been since April 2020, they recovered and began going up through October and November.

By Jan. 3, 2023, spot gold prices had peaked at just under $1,850 per troy ounce before settling at around $1,838 per ounce. U.S. gold futures also went up by 1% to trade at $1,844.20 per ounce as gold recovered from the September 2022 low.

Thanks to increasing recession expectations, rising gold purchases from central banks and market turbulence, gold prices have seen a steady increase since the start of November. With gold prices achieving a six-month high last week, experts predict that the precious yellow metal will see even more bullish action throughout 2023.

Saxo Bank head of commodity strategy, Ole Hansen, predicts a “price friendly 2023” on the back of stock market and recession valuation risks. Hansen noted that gold prices would also be supported by the prospect of a weaker greenback, inflation not returning to expected sub-3% levels by the end of the year and a peak in central bank interest rates.

Furthermore, Hansen said, moves by several central banks to buy a record amount of gold in lieu of dollars were set to continue into 2023 and would provide a soft floor under the gold market. He suggested that two incoming key events would have significant consequences on gold prices: the unveiling of the minutes from the latest Fed meeting as well as the U.S. job report.

Most experts have predicated their 2023 outlooks on global markets on the performance of monetary policy. Last year was characterized by consecutive interest rate hikes by the U.S. Federal Reserve and other central banks around the world due to possible recessions and sluggish economic growth. With inflation expected to remain high in most of the world’s largest economies, top economists are divided on whether central banks will cut benchmark interest rates toward the end of 2023. If central banks make a full dovish pivot at some point in the year, strategists believe the move could have a significant impact on gold prices.

AuAg ESG Gold Mining ETF manager Eric Strand stated in December that gold would see all-time high prices in 2023 of more than $2,100 per ounce. If central banks pivot on their interest rate hikes and take a more dovish stance in 2023, Strand believes this move will result in a surge in gold prices of at least 20%. Such a surge would be good tidings for the stakeholders in major mining companies, such as Newmont Corporation (NYSE: NEM) (TSX: NGT).

Newmont Corporation (NEM), closed Monday's trading session at $52.22, off by 0.89201%, on 7,561,780 volume. The average volume for the last 3 months is 9.826M and the stock's 52-week low/high is $37.45/$86.37.

QuantumScape Corp. (QS)

InvestorPlace, Schaeffer's, StocksEarning, MarketClub Analysis, The Street, The Online Investor, MarketBeat, QualityStocks, Daily Trade Alert, Top Pros' Top Picks, TipRanks, wyatt research newsletter, Atomic Trades, Trades Of The Day, CNBC Breaking News and BUYINS.NET reported earlier on QuantumScape Corp. (QS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

This year, the car company that manufactures Hyundai and Kia cars as well as the well-known EV6 and Ioniq 5 auto cars, announced plans to boost sales by 10% globally while also speeding up the electrification process for EVs. Hyundai has released the 2023 projections even though the company’s 2022 sales goals were unmet because of supply chain issues that brought about shortages of semiconductor chips as well as other critical auto component parts.

Supplies of semiconductor chips used to control the electronics in vehicles have been globally unpredictable. This is due in part to COVID-19 regulations seen in China, which made it difficult for car manufacturers to meet demand.

Nonetheless, Hyundai stated that it intended to respond freely to changes in the market as well as the latest environmental rules by speeding up its switch to electric vehicles; by doing so, the company hopes to increase its share of the market and engage in profitable business ventures in 2023. It also intends to achieve its objectives by streamlining its regional sales, production procedures and logistics.

The company said it aimed to sell 4.3 million vehicles across the globe in 2023. Its Kia and Hyundai cars are some of the top-selling car brands in the United Kingdom, accounting for around 11.5% of market share. This is in comparison to the 3,900,000 vehicles it sold in 2022, which fell short of the revised target of 4,010,000 vehicles, down from the original target of 4,300,000

Hyundai praised its 2022 performance, acknowledging the 2.9% rise in international sales despite operating its business in a difficult environment brought on by the recurring pandemic and auto parts supply problems. The increase was partly due to the auto market slowly recovering from the pandemic. Nonetheless, South Korean sales fell by 5.2%.

In the months ahead, Hyundai is set to introduce a high-performance EV, the first one for the company.

Hyundai announced its hopeful sales projections after electric car manufacturer Tesla disclosed that it actually delivered a record-breaking 1,300,000 cars in 2022. Even though the sales were 40% higher than the year ago, there were indications of slowing down in the final quarter, when Tesla only delivered 405,000 vehicles as opposed to the 430,000 vehicles predicted by analysts.

Car sales are expected to fall in 2023 as consumers worry about the economy and pay close attention to increasing rates of interest. This will definitely cause further challenges for the auto sector, and startups such as QuantumScape Corp. (NYSE: QS) may have to get creative in order to not only survive but also thrive in such an environment.

QuantumScape Corp. (QS), closed Monday's trading session at $6.3, up 11.7021%, on 9,841,346 volume. The average volume for the last 3 months is 254,483 and the stock's 52-week low/high is $5.11/$22.21.

The QualityStocks Company Corner

Vision Energy Corp. (OTCQB: VENG)

The QualityStocks Daily Newsletter would like to spotlight Vision Energy Corp. (OTCQB: VENG).

• A total of 194 parties (including the European Union) have joinedthe Paris Agreement intending to reach carbon-neutral status by2050 to reduce the impact of global climate change

• Vision Energy’s Green Energy Hub in the Netherlands will help withimport, storage, and distribution of low-carbon renewable fuels andhydrogen carriers

• The company plans for first operations to commence in 2026, withthe terminal running 24 hours a day, 365 days a year

Climate change is a global emergency with negative impacts beyondnational borders – requiring cooperation and collaborativesolutions amongst nations and world leaders. The Paris Agreement isa legally binding international treaty that sets long-term goals toguide all nations, with 194 parties (193 States plus the EuropeanUnion) joining the Agreement so far. The goals of the ParisAgreement include:

• Substantially reducing global greenhouse gas emissions to limit theglobal temperature increase in this century to 2 degrees Celsiuswhile pursuing efforts to limit the increase even further to 1.5degrees,

• Reviewing countries’ commitments every five years, and

• Providing financing to developing countries to mitigate climatechange, strengthening resilience, and enhancing abilities to adaptto climate impacts.

The Agreement provides a durable framework for guiding the globaleffort and shifting toward net-zero emissions worldwide.Implementation of this Agreement is also essential for achievingSustainable Development Goals.

Vision Energy (OTCQB: VENG) is a forward-looking energy company developing assets andsolutions for the commercial, industrial and transportationsectors. Leveraging its proven track-record in site and assetprocurement, accelerating development, and permitting processes,plant design, and grid integration to facilitate low-carbon energyproduction, supply, and distribution. Through its wholly-ownedsubsidiary, Evolution Terminals BV (“ETBV”), Vision Energy ispioneering a Green Energy Hub terminal development project for theimport, storage, and distribution of low-carbon renewable fuels andhydrogen carriers, strategically located in the North Sea Port ofVlissingen at the mouth of the Westerschelde estuary in theNetherlands.

Vision Energy Corp. (OTCQB: VENG) (“Vision Energy”) is a forward-looking energy company developing carbon reduced solutions for the commercial, industrial and transportation sectors. Vision Energy is leveraging its team’s proven track-record in site and asset procurement, accelerating development and permitting processes, plant design, and grid integration to facilitate low-carbon energy production, supply and distribution. The company is pursuing reliable offtake relationships and operating partnerships with energy industry participants and end users seeking carbon abatements across feedstock and fuels. Vision Energy is committed to providing low carbon energy solutions with maximized yield, with projects designed to exploit existing gas and power infrastructure, to integrate and facilitate import and/or distribution of reduced-carbon energy to domestic and global supply chains.

The company believes that hydrogen and liquid carriers of hydrogen are the most reliable alternatives to fossil fuels. Hydrogen is anticipated by many energy analysts to become more widely competitive as an alternative mobile energy source as early as 2030, as economies of scale drive down costs.

According to the International Energy Agency report ‘Hydrogen in North-Western Europe (2021)’, the region is well placed to lead hydrogen adoption as a clean energy source. Today, this region comprises approximately 5% of global hydrogen demand and 60% of European demand. Moreover, the region is home to the largest industrial ports in Europe, where much of this hydrogen demand is located, and presents a well-developed natural gas infrastructure connecting these ports with other industrial hubs. This gas network could be partially repurposed to facilitate hydrogen delivery from production sites to demand centers. Governments in this region also have ambitious goals for greenhouse gas emissions reduction and there is strong political interest in hydrogen as a pathway to maintaining industrial activity in the region.

Vision Energy is based in Jersey City, New Jersey.

Projects

Through wholly owned subsidiary Evolution Terminals BV, Vision Energy is pioneering a Green Energy Hub development project for the import, storage and distribution of low-carbon renewable fuels and hydrogen carriers, strategically located in the North Sea port of Vlissingen at the mouth of the Westerschelde estuary in the Netherlands. This Green Energy Hub is positioned to be the first terminal in Europe focused on green and low-carbon energy products.

Vision Energy is at an advanced stage of planning for the construction of its Green Energy Hub and is on schedule to file for the remaining construction and environmental permits by December 2022. The Green Energy Hub design is capable of receiving seagoing vessels, barges and coasters, served by a dedicated deep-water jetty as well as rail and truck loading infrastructure that will enable direct access to purpose-built storage and handling facilities for low-carbon fuels and hydrogen carriers, including ammonia, methanol and liquid organics. Phase 1 capital expense is estimated at approximately €450 million, including jetty infrastructure, and will provide for up to 400,000 cubic meters (CBM) of storage capacity with land already secured for future expansion.

Market Opportunity

In Northwestern Europe, the market for green hydrogen, or hydrogen produced by renewable energy, is growing rapidly. The current hydrogen demand projections outstrip the scheduled production for the next five to 10 years.

The company believes that all producers will face high demand. Moving beyond its initial Green Energy Hub, Vision Energy is focused on countries where governments support a regulatory standard that promotes hydrogen production and consumption. Many governments have established various incentives and financial mechanisms to accelerate and promote the use of hydrogen as a renewable energy source.

The EU, through its European Green Deal, has set an objective to become climate-neutral by 2050, implying the near total phase-out of fossil fuels in the EU energy system, and many countries are working to put in place subsidy programs for the development of green hydrogen facilities in anticipation of this goal.

Vision Energy projects its total addressable market at €10 billion by 2050.

Management Team

Andrew Hromyk is CEO of Vision Energy. He has supported and operated chemical and energy operations in the Permian Basin, central and south Texas, Arkansas, Alberta and internationally. An active investor, he has been involved with companies developing a diverse range of technologies, from enhanced and conventional hydrocarbon recovery processes to wireless infrastructure. He has participated in numerous industrial and commercial real estate developments. He also has served as a director of several private companies that became publicly traded on Nasdaq, NYSE and TSX. He studied economics at Chaminade University and the University of British Columbia.

Arron Smyth is Executive Vice President of Corporate Development at Vision Energy. He has more than 18 years of experience in financial services, investment banking, business leadership and operations in both developed and emerging markets. Since 2018, he has been Managing Director Europe for the First Finance group of companies, developing and supporting the group’s private equity investments and projects, including Evolution Terminals, the Netherlands-based developer of tank terminal and port infrastructure for the bulk storage and handling of clean and sustainable energy products.

Matthew Hidalgo is CFO of Vision Energy. He has over 15 years of experience in accounting, operations, finance, corporate restructuring and integrating acquisitions. He is a Managing Partner at Turquino Equity LLC, a private equity investment firm. Formerly, he was the controller and operations manager for the largest subsidiary of WPCS International Incorporated. Prior roles included managing accounting functions for several Australian subsidiaries. After graduating from Penn State with a bachelor’s degree in accounting, he began his career at PricewaterhouseCoopers.

Vision Energy Corp. (OTCQB: VENG), closed Monday's trading session at $2.05, up 3.0151%, on 73,251 volume with 375 trades. The average volume for the last 3 months is 57,207 and the stock's 52-week low/high is $1.04999995/$5.63000011.

Recent News

Cybin Inc. (NEO: CYBN) (OTC: CYBN)

The QualityStocks Daily Newsletter would like to spotlight Cybin Inc. (NEO: CYBN) (NYSE American: CYBN).

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelicsto Therapeutics(TM), is discussing upcoming priorities andnear-term milestones regarding the status of its two clinicalprograms aimed at addressing multiple mental health conditions:CYB003 and CYB004. Designed for the treatment of Major DepressiveDisorder (“MDD”), CYB003 is currently in a phase 1/2a clinicaltrial. CYB003 is a deuterated psilocybin analog. CYBN anticipatesreleasing an interim readout from the trial by the end of February2023, which will provide an initial understanding of the safety andpharmacokinetic (“PK”) profile of the substance in humans. Thisinterim data will be key in identifying the necessary dose-ranginginformation for the ongoing trial as well as future clinicalstudies. Designed for the treatment of anxiety disorders, CYB004 isin a phase 1 exploratory trial designed to help identify safety anddosing data for the future clinical development of the deuteratedDMT. The update noted that the CYB004-E trial has not shown anyclinically significant safety or tolerability issues. Cybin alsoanticipates releasing an update on its CYB004 program by the end ofFebruary 2023. “Cybin enters 2023 with the potential to reach anumber of value-driving milestones, including importantadvancements across our development pipeline,” said Cybin CEO DougDrysdale in the press release. “These priorities will provideimportant information to help strengthen our business as wecontinue to focus on the progression of our innovativeinvestigational therapies aimed at addressing the significant unmetneed for people struggling with mental health conditions.”

To view the full press release, visit https://ibn.fm/Ks4Nb

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) is a Canada-based life sciences company focused on the pharmaceutical development of psychedelic products, as well as the functional mushroom market.

The early-stage company boasts an experienced management team featuring industry veterans from pharmaceutical and consumer product backgrounds who have run multiple clinical trials and collectively helped facilitate billions of dollars in product revenues. The team is dedicated to the development of products and protocols within the psychedelic, pharmaceutical and nutraceutical industries.

In particular, Cybin aims to further build upon and expand its intellectual property (IP) portfolio, which is structured around unique psilocybin delivery mechanisms that target a number of different therapeutic indications. In addition, the company has dedicated itself toward furthering its research and IP within the fields of synthetic compounds, extraction methods, the isolation of chemical compounds, new drug formulations and protocol regimes.

Serenity Life Sciences & Natures Journey Inc.

The company’s business model is centered around its two core subsidiaries, Serenity Life Sciences and Natures Journey Inc., which comprise Cybin’s two-pronged approach toward delivering fungi-derived psychedelic and medicinal products.

Serenity Life Sciences is focused on furthering research and development of psilocybin-based medications. Psilocybin is found in certain species of mushrooms and is a non-habit forming, naturally occurring psychedelic compound. Research into psilocybin has shown positive results for the treatment of depression, anxiety, PTSD, addiction, eating disorders, ADHD and other indications.

Natures Journey Inc. operates the Journey brand, which specializes in developing proprietary medicinal mushroom products that target and promote mental wellness, immune boosting detoxification and overall general health and wellbeing.

Partnership with the Toronto Centre for Psychedelic Science (TCPS)

Staying true to its axiom of being a research-first medicinal mushroom life sciences company, Cybin recently announced its entry into a strategic partnership with the Toronto Centre for Psychedelic Science (TCPS), with the goal of furthering its ongoing psilocybin research efforts and expanding Cybin’s psilocybin IP portfolio (http://nnw.fm/9EUkI).

“While there is evidence to support psilocybin as a treatment for certain indications, the Toronto Centre for Psychedelic Science is taking a clinical approach to prove or disprove the safety and efficacy of psilocybin-based microdosing through an open science approach,” Paul Glavine, CEO of Cybin, stated in a news release.

“We are excited to join forces with Cybin and to offer our expertise. A number of firms had approached TCPS, but Cybin demonstrated a superior commitment to high-quality research and integrity in product development. Our high standards for scientific rigor and transparency will find a fitting home within the culture Cybin is cultivating in Canada and abroad,” Thomas Anderson, co-founder of the Toronto Centre for Psychedelic Science, added.

Journey’s Product Monetization & Market Potential for Nutraceutical Supplements

Although Cybin is at the forefront of companies seeking to conduct clinical trials aimed at gaining regulatory approval for psilocybin and other psychedelic products, the company has also placed a great deal of emphasis on generating meaningful revenue from its very outset.

Cybin’s Journey brand has is launching a range of supplements comprised of popular fungi-derived ingredients such as Reishi, Lion’s Mane and Cordyceps. Purported to aid focus and concentration while promoting neurogenesis, Journey’s range of nutraceutical products provides Cybin with a crucial foothold within the non-psychedelic legal supplement market, which is valued at over $25 billion globally and growing at a 9% year-over-year rate.

Pharmaceutical Psychedelics

In addition to the company’s range of non-psychedelic supplements, Cybin has plans to carry out a clinical trial with a new delivery system for its psilocybin-based medications later this year. Ultimately, the company aims to enter into technology transfer agreements with global pharmaceutical companies after phase 1 & phase 2 clinical trials are complete in order to accelerate regulatory approvals in major indications in global markets with entire lifecycle product management.

With products such as psilocybin truffles already legal in nations such as the Netherlands, Jamaica and Bulgaria, Cybin has positioned itself to capitalize on an eventual legalization of psychedelic mushroom-derived products in the future. Working within a regulatory environment with strong similarities to that which dealt with cannabis prior to the industry’s eventual legalization by the Canadian government in 2018, Cybin is laying the groundwork for the moment pharmaceutical psychedelics gain acceptance in North America and abroad.

Amalgamation Agreement and Financing

Cybin recently announced its entry into an amalgamation agreement dated June 26, 2020, with Clarmin Explorations Inc. (TSX.V: CX) and 2762898 Ontario Inc., a wholly owned subsidiary of Clarmin (http://nnw.fm/w04LH). Completion of the transactions contemplated in the amalgamation agreement will result in the reverse takeover of Clarmin by Cybin.

In connection with the proposed transaction, Cybin plans to complete a “best-efforts” brokered private placement of subscription receipts of Cybin, with a syndicate of agents co-led by Stifel Nicolaus Canada Inc. (Stifel GMP) and Eight Capital, to raise a minimum of C$14 million ($10 million) and a maximum of C$21 million ($15 million), with a 15% agents’ option.

To date, Cybin has raised approximately C$10,400,000 through an initial financing round and its series A financing round.

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), closed Monday's trading session at $0.495, up 25.6664%, on 3,149,885 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $26.10/$.

Recent News

India Globalization Capital Inc. (NYSE American: IGC)

The QualityStocks Daily Newsletter would like to spotlight India Globalization Capital Inc. (NYSE American: IGC).

Last week, the state of New York launched its first legal dispensary for recreational cannabis. The dispensary, which is operated byHousing Works, is the first legal shop in what is expected to beone of the most profitable markets for marijuana in the country.Housing Works is a not-for-profit organization that is minority controlled andserves individuals who were formerly incarcerated as well as thehomeless and individuals diagnosed with HIV and AIDS. New Yorklegalized the recreational use of marijuana in March 2021. However,unauthorized sellers have been selling the drug for years.Consumers’ purchasing regulated and high-quality marijuana fromlegal dispensaries is expected to shrink the illicit market in thestate. Cannabis regulators also expect that the opening of legalstores will help ensure that users are buying safe products. Thelegal sale of recreational marijuana in New York State is coming ata time when many companies, including India Globalization Capital Inc. (NYSE American: IGC), are investing heavily in developing cannabis-based therapeuticformulations, which can win FDA approval and be availed to patientsin need through the hospital system of the country.

India Globalization Capital Inc. (NYSE American: IGC), through subsidiary IGC Pharma, develops, patents, and markets advanced THC-based drug formulations for the treatment of symptoms related to various diseases including but not limited to Alzheimer’s disease, Tourette syndrome, chronic pain, and pet seizures.

IGC’s leading drug candidate, IGC-AD1, has completed Phase 1 of a safety and tolerability trial and entered Phase 2 trials for treating agitation in patients with Alzheimer’s dementia, the first study in humans of a natural tetrahydrocannabinol (THC) compound plus another molecule (www.clinicaltrials.gov). As of September 2022, the IGC trial is the only ongoing Phase 2 trial of a natural THC-based formulation on Alzheimer’s patients.

The company’s other drug candidate, TGR-63, is an enzyme inhibitor that has shown in preclinical trials the potential to reduce neurotoxicity in Alzheimer’s cell lines. Both drug candidates have shown their ability to ameliorate beta amyloid plaques in Alzheimer’s cell lines and improve memory in Alzheimer’s mouse models. Beta amyloid plaques are a key hallmark of Alzheimer’s and an important target of Alzheimer’s pharmaceutical drug development.

Neuro Psychiatric Symptoms (NPS) are not only debilitating for Alzheimer’s patients; they also place an immense emotional burden on their caregivers. Beyond reducing symptoms, IGC-AD1’s active molecules and TGR-63 have also shown promise in preclinical trials to reduce important hallmarks of Alzheimer’s including plaques and tangles, as well as improving the treatment of memory loss.

Over the past eight years, the IGC team has amassed a deep knowledge of cannabinoid science, including extraction, isolation, purification, and development. The company’s strategy is to leverage its unique end-to-end capabilities, platform, and expertise to develop a class-leading program and bring it to market quickly and cost efficiently to treat neurodegenerative diseases such as Alzheimer’s.

The company also has a family of cannabidiol (CBD)-based consumer products (www.Holief.com) such as pain relief creams, pain relief gels, purpose gummies, tinctures, and capsules targeting women’s wellness, with a particular focus on premenstrual syndrome (PMS) and dysmenorrhea (period cramps). In addition, the company targets individuals that need sleep-aids with its specially formulated low melatonin cannabinoid gummies.

IGC has also introduced a low-calorie CBD- and caffeine-infused energy beverage brand (www.SundaySeltzer.com) that is currently available for purchase. The company’s brands are founded on the belief that effective natural solutions should be affordable and accessible to everyone. As the demand for natural products targeting women’s wellness and energy drinks continue to grow, these products are seeing strong traction in the market.

The company operates three facilities – a large GMP (Good Manufacturing Production Standards) certified facility that includes extraction, distillation, and manufacturing, in Washington State; a GMP-211 (pharmaceutical) grade facility in Maryland; and a facility licensed for controlled substances including cannabis in Bogota, Colombia, with complete access to legal licensed cannabis where the company conducts its testing.

In addition, the company’s development under Magistral Formulations is approved by INVIMA (Colombia National Food and Drug Surveillance Institute) to treat neurological disorders, non-oncological chronic pain, and mental disorders.

IGC’s intellectual property (IP) portfolio comprises of eight patents that it controls and seven patent applications. The portfolio includes #11,446,276, a patent for extreme low dose THC treatment of Alzheimer’s that was granted in September 2022.

The company is headquartered in Potomac, Maryland.

IGC-AD1

IGC-AD1 is the company’s leading drug candidate for the treatment and relief of Alzheimer’s symptoms. A significant amount of research on Alzheimer’s cell lines has shown that the active agents in IGC-AD1 reduce plaques and neurofibrillary tangles that are the hallmarks of Alzheimer’s. Further, micro-dosing of THC, as shown in cell lines, could increase the functioning of mitochondria and potentially promote the growth of new neural pathways (neurogenesis). The research shows that micro-dosing of THC affects the brain radically differently from the normal higher dosing of THC.

While there is a significant body of research showing that THC is neuro-toxic at normal levels of dosing, micro-dosing of THC has been shown to be non-toxic to neurons. With the results of these preclinical studies, the company developed an oral formulation, IGC-AD1. The company recently completed a safety and tolerability Phase 1 trial on Alzheimer’s patients and has initiated a Phase 2, multi-site, double-blind, randomized, placebo-controlled trial of the safety and efficacy of IGC-AD1 on agitation in participants with dementia due to Alzheimer’s disease at sites in the U.S. and Canada. IGC expects the Phase 2 trial to take between 9 and 12 months to complete, barring unknown factors such as, for example, a resurgence of COVID and the enforcement of lockdowns and travel restrictions.

With further successful trials and FDA approvals, IGC hopes to bring a drug based on natural THC as an effective treatment for agitation in Alzheimer’s to market.

TGR-63

The company’s other molecule, TGR-63, has been shown to reduce the neurotoxicity that impacts memory loss in preclinical trials with mice. On a dose dependent manner, transgenic Alzheimer’s mice treated with TGR-63 showed improvement in memory relative to control.

Both drug candidates, IGC-AD1 and TGR-63, have shown their ability to reduce the brain plaques associated with memory loss in Alzheimer’s in mice.

With further successful trials and FDA approvals, IGC hopes to bring TGR-63 as a treatment for Alzheimer’s disease to market.

Market Opportunity

Alzheimer’s disease impacts over 55 million people worldwide and about 5.5 million individuals in the U.S. Over 70% of these patients face debilitating symptoms, including anxiety, depression, and agitation (Mendez, 2021). Agitation in dementia patients can include excessive physical movement and verbal activity, restlessness, pacing, belligerence, aggression, screaming, crying, and wandering.

In 2020, the estimated healthcare costs for Alzheimer’s disease in the U.S. were $305 billion. Medicare and Medicaid covered about 70% of those costs, leaving considerable burden on patients and families. At the current rate of growth of Alzheimer’s and other dementia diagnoses, those costs are estimated to reach over $1 trillion by 2050.

Currently, there are no FDA-approved medications to alleviate the symptoms of dementia due to Alzheimer’s disease, providing a tremendous opportunity for formulations that can have an impact on quality of life and disease progression.

Management Team

Richard Prins has been chairman at IGC since 2012 and served as an independent director since 2007. From March 1996 to 2008, he was the Director of Investment Banking at Ferris, Baker Watts, Incorporated. Prins served in a consulting role to RBC until January 2009. He currently volunteers full time with a non-profit organization, Advancing Native Missions, and is a private investor. Since February 2003, he has been on the board of Amphastar Pharmaceuticals Inc. He holds a bachelor’s degree from Colgate University and an MBA from Oral Roberts University.

Ram Mukunda is CEO and President of IGC. He has been the chief inventor and architect of most of the company’s patent filings and is responsible for the company’s strategic positioning. Prior to IGC, he was founder and CEO of Startec Global Communications, which he took public in 1997. He served as Strategic Planning Advisor at Intelsat, a communications satellite services provider. From 2001 to 2003, he was a Council Member at Harvard’s Kennedy School of Government, Belfer Center of Science and International Affairs. He was named the 1998 Ernst & Young Entrepreneur of the Year. He holds bachelor’s degrees in electrical engineering and mathematics, and a master’s degree in engineering from the University of Maryland.

Dr. Jagadeesh Rao is the company’s Principal Scientist. His career spans two decades in the public sector and product R&D for Johnson & Johnson. He leads IGC’s scientists in the development of pharmaceutical and OTC products. He worked for the federal National Institutes of Health, and for the National Institute on Drug Abuse. His Ph.D. in Neurochemistry is from the National Institute of Mental Health & Neurosciences in India. He did postdoctoral training at the University of Illinois-Chicago.

Claudia Grimaldi is a Director, Vice President, Principal Financial Officer, and Chief Compliance Officer for IGC. She also serves as a Director/Manager Director for some of the company’s subsidiaries. She graduated with highest honors from Javeriana University in Colombia with a bachelor’s degree in psychology. She holds an MBA, graduating with highest honors, from Meredith College in North Carolina. In addition, she has attended the Darden School of Business Financial Management Executives program and the Corporate Governance Program at Columbia Business School. She is currently pursuing her Directorship Certification with the National Association of Corporate Directors. She is fluent in both English and Spanish.

India Globalization Capital Inc. (NYSE American: IGC), closed Monday's trading session at $0.3355, up 3.5494%, on 291,349 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.2785/$1.16.

Recent News

Coyuchi Inc.

The QualityStocks Daily Newsletter would like to spotlight Coyuchi Inc.

  • The California Cotton & Climate Coalition (“C4”) wascreated to build capacity within all stakeholders to grow,source, and develop climate-beneficial, farm-forward textilesand supply chains
  • Cotton grown through C4 carries the Climate Beneficial(TM)trademark, which requires a rigorous verification processduring the lifecycle of the product with an emphasis onenhancing biological life
  • Coyuchi recently reported an upward trajectory of 26 percentyear-over-year net sales growth and an overall revenue climb of$33.3 million – promoting investment opportunities for thepublic through Regulation A+

Coyuchi, the gold standard in sustainable luxury home goods, uses 100%organic cotton to manufacture all of its textiles. The company wasbuilt on four foundational pillars: protecting the planet,innovating circular design, living sustainably, and enriching thecommunity. In line with this mission, Coyuchi has joined acoalition of companies working together to evolve California’scotton-growing industry.

Coyuchi is the gold standard in sustainable luxury home goods. The company offers sustainably produced luxury organic bedding, sheets, towels, apparel, and other home goods for the environmentally conscious home. With a timeless, coastal-inspired aesthetic, Coyuchi uses only 100% organic cotton materials to manufacture all of its textiles.

The Company was built upon four foundational pillars: protect the planet, innovate circular design, live sustainably, and enrich the community. These guiding principles have proven an effective market strategy. In 2021, Coyuchi earned $33.3 million in net sales, amounting to 26% YoY growth (the industry average is only 5%). It also experienced 2x customer growth to 200,000 active customers, averaging a 35% customer repeat purchase rate.

With a seasoned leadership team, a robust e-commerce shopping experience, and a healthy customer base that drives the fast-growing organic luxury market, Coyuchi is prepared to propel a new phase of growth as the rest of the world finally awakens to sustainability at scale.

A Lucrative Market Ripe for the Taking

The global market for organic bedding, which was estimated at $814.3 million in 2020, is projected to reach $1.1 billion by 2027, growing at a CAGR of 4.9% over that period, according to Research and Markets. More specifically, the domestic organic bedding market is estimated at $240.1 million in 2020, according to Statista. Overall, the U.S. market for home textiles is currently valued at $25 billion annually, and, with a forecast annual growth rate of 5%, it is expected to reach $30 billion by the end of 2025.

Grand View Research reported in 2020 that shifting consumer preference toward high-end lifestyle products is a key factor driving the growth of the organic bedding market. Seventy-four percent of consumers are willing to pay more for sustainable products – a consumer preference that has steadily increased over the last few decades. Millennials especially favor ethical consumption over price when purchasing goods and services, with 83% of millennials reporting that they want the brands they purchase from to align with their beliefs and values (https://ibn.fm/PANNV). With a majority millennial customer base, Coyuchi is poised to capitalize on this trend.

Industry Defining Sustainability Practices

For 30 years, Coyuchi has explored organic farming and sustainable textiles and guarantees the highest environmental and ethical standards through a number of certifications such as The Global Organic Textile Standard (GOTS), Fair Trade Certified, and MADE SAFE®.

Coyuchi continues to push the organic textile market forward through its circularity initiatives and by supporting cross-industry sustainability advocates. Coyuchi’s mission to bring beauty and comfort to every home without sacrificing the health of our planet has resulted in a number of important sustainability checks and balances.

  • A Circular Business Model: Coyuchi has cultivated a holistic 360-degree approach that contributes to the fight against climate change with its take back and recycling program, 2nd Home™. In 2017, it became the first luxury home brand to implement such an initiative, and, since then, the company has eliminated 68,758 lbs. of toxic chemicals from homes and renewed 6,000 lbs. of textiles.
  • The Coyuchi Climate Council: In early 2022, Coyuchi introduced a cross-disciplinary council with a goal of Net Zero Emissions by 2025 and Net Positive Emissions by 2030. The Coyuchi Climate Council brings together influential minds across fashion, regenerative farming, and sustainability who have the knowledge and experience necessary to achieve climate change.
  • C4: The California Cotton & Climate Coalition: Most recently, Coyuchi announced it is a founding member of C4, which includes innovative, sustainable fashion, apparel, and personal care brands like MATE the Label, Outerknown, Reformation, and Trace. Working together pre-competitively, C4 creates a structure for investing in regionally grown, Climate Beneficial™ cotton and directly supports the livelihoods of the farmers that grew it. Coyuchi is the only home industry brand currently involved in the project.

Omnichannel Business Model

Coyuchi differentiates itself through an omnichannel and circular business model, both of which have proven a clear draw for customers. It was an early adopter of an e-commerce sales and marketing approach (over 80% of its sales are directly through coyuchi.com), creating a distinct advantage over incumbents and start-up newcomers in the luxury space. This has resulted in a high lifetime value customer, luxury retail partners such as Nordstrom, and a flagship store in Marin County.

Coyuchi’s Organic Textile Products

Coyuchi’s product assortment consists of consciously designed bedding, bath, apparel, and lifestyle products spread across about 1,400 SKUs. The company believes that its product assortment, produced from 100% organic cotton with Global Organic Textile Standard (GOTS) certification, provides it with a significant competitive advantage. GOTS is the world’s leading textile processing standard for organic fibers, ensuring the organic status of textiles after harvesting raw materials through environmentally and socially responsible manufacturing all the way to labeling, a major environmental and social benefit over conventional cotton product production.

Coyuchi’s focused product assortment consists of four core categories:

  • Bedding – A full suite of sustainable, organic, and high-quality sheets, duvet covers, blankets, and throws.
  • Bath – A luxurious line of towels, bath rugs, and mats.
  • Apparel – Premium apparel for men and women, including robes, sweaters, pants, and pajamas.
  • Lifestyle – The lifestyle category offers 135 SKUs, from organic napkins to crossbody totes.

Management Team

Eileen Mockus is President and CEO at Coyuchi. She has more than 25 years of experience in retail, having held positions in textile development at Patagonia, Pottery Barn Teen, and The North Face. She earned a bachelor’s degree in textiles and clothing from UC Davis and an MSBA from San Francisco State University.
Sejal Solanki is Chief Marketing Officer at Coyuchi. She previously served as the company’s Vice President of E-Commerce. Before joining Coyuchi, she worked at teen clothing giant Charlotte Russe. She oversees the company’s digital marketing, site experience, brand marketing, and e-commerce strategy.

Marcus Chung is Coyuchi’s COO, overseeing supply chain, sourcing strategy, sustainability, and IT. He previously held positions at notable direct-to-consumer brands Third Love and Stitch Fix, as well as national retailer The Children’s Place. He holds a bachelor’s degree from Wesleyan University and an MBA from UC Berkeley’s Haas School of Business.

Margot Lyons is Director of Sustainability and Sourcing at Coyuchi, where she works with strategic partners to ensure all the company’s product sustainability standards are met. She received a master’s degree in textiles and clothing from UC Davis.

Use of Proceeds

This round of funding will be used to increase Coyuchi’s enterprise value through expanded marketing, product category expansion, continued physical presence, and B2B strategic partnerships with wholesalers, and online marketplaces.

Recent News

chart

Correlate Infrastructure Partners Inc. (OTCQB: CIPI)

The QualityStocks Daily Newsletter would like to spotlight Correlate Infrastructure Partners Inc. (OTCQB: CIPI).

Correlate, through its two subsidiaries, Correlate, and Solar SiteDesign, is offering a complete suite of proprietary clean energyassessment and fulfillment solutions, viewing such solutions asintegral to mitigating the effects of climate change

The WMO estimated that 2022 would likely be 1.15 degree Celsiuswarmer than pre-industrial times. It also projected, with a 93%probability, that one of the next five years would be warmer than2016, which was the warmest year on record at about 1.28 degreeCelsius hotter than pre-industrial times

The spike in temperatures, according to the WMO, will be influencedmainly by countries’ suboptimal efforts to enforce effectiveclimate change action, as has been the case over the past few years

Correlate continues to drive forward the discussion around cleanenergy, while also reducing the barrier of entry, allowing realestate owners, businesses, and entire industries, to go green

Correlate Infrastructure Partners (OTCQB: CIPI) is forging a path for big and small companies to utilize energymore efficiently while lowering their overall carbon emissions.Through its two subsidiaries, Correlate and Solar Site Design, thecompany offers a complete suite of proprietary clean energyassessment and fulfillment solutions, stemming from theunderstanding that scaling distributed clean energy solutions iskey to mitigating the growing effects of climate change.

Correlate Infrastructure Partners Inc. (OTCQB: CIPI), formerly Triccar Inc., through its two subsidiaries, Correlate and Solar Site Design, offers a complete suite of proprietary clean energy assessment and fulfilment solutions for the commercial real estate industry. The company believes scaling distributed clean energy solutions is critical in mitigating the effects of climate change. CIPI is at the forefront in creating an industry-leading energy solution and financing platform for the commercial and industrial sector. The company sees tremendous market opportunity in reducing site-specific energy consumption and deploying clean energy generation and energy efficiency solutions at scale.

The opportunity exists to remove friction between today’s legacy finance process and the needed clean-energy upgrades developed within the company’s program technologies. For the U.S. to reach its 2050 carbon goals, 200,000 commercial buildings must be retrofitted every year until that date. That represents approximately a 5-10x increase over the 2022 industry process run rate.

CIPI announced completion of its acquisition of 100% of the equity of Correlate Inc. and Loyal Enterprises LLC dba Solar Site Design on December 28, 2021. The company notes these acquisitions occurred at a key inflection point of its growth. CIPI currently enjoys channel and sales partnerships with Fortune 250 companies and a strong, proven industry network.

The company’s transparent, leading-edge model changes value delivery for both facility owners and proven solution providers seeking scale. CIPI believes its rapid growth is due to industry demand for actionable, cashflow positive energy programs and the underlying carbon reduction mandates taking effect globally.

CIPI has filed with the SEC for a name change to Correlate Infrastructure Partners Inc., which will more closely reflect its new platform and growth focus. The company has been aggressively moving to rebrand, with efforts including a revised website, investor presentation materials and an investor relations awareness campaign. The company’s shares will continue to trade on the OTCQB Venture Market under the current ‘CIPI’ ticker symbol until changes are approved.

Subsidiaries

Correlate, founded in 2015, is a portfolio-scale development and finance platform offering commercial and industrial facilities access to clean electrification solutions focused on locally-sited solar, energy storage, EV infrastructure, and intelligent efficiency measures. Its unique data-driven approach is powered by proprietary analytics, concierge subscription services, and a highly scalable national fulfillment network to help building owners profit from fully funded, turnkey decarbonization and facility health programs. The platform is designed for commercial and industrial real estate owners seeking to significantly improve net operating income while meeting carbon reduction goals. The platform provides energy programs for commercial property portfolios and requires no upfront capital. Client organizations reduce their risk and generate more profits by leveraging Correlate’s unique payment programs to put more cash in the bank. Deploying Correlate’s strategic energy programs and energy management systems allows property-owning organizations to complete big energy changes across their portfolios.

Solar Site Design, founded in 2013, is a U.S. Department of Energy Sunshot Catalyst winner that provides customer acquisition and project development tools for the commercial solar industry. Its commercial marketplace platform connects highly qualified project opportunities to leading solar construction companies nationwide. The Solar Site Design platform gives commercial and industrial property owners access to the best price for a commercial solar system. Commercial solar analysts provide property owners a site assessment and working project proposal. Solar Site Design’s team of solar engineers finalize the design while approved financing providers help clients explore financing options for their projects. Then, approved contractors in Solar Site Design’s Marketplace bid on the projects, ensuring commercial and industrial property owners get the best estimates for their projects. Solar Site Design’s marketplace process promotes transparency and fair pricing. Its team of experts has nearly 20 years of experience in the solar industry. Only reputable, experienced, certified (NABCEP), licensed, bonded and insured contractors are accepted into the Solar Site Design Marketplace.

Market Outlook

CIPI is in a rapidly growing market with a unique offering to address a total market of more than 5.9 million commercial buildings in the United States, according to the U.S. Energy Information Administration. Currently, the company’s wholly owned subsidiaries, Correlate and the Solar Site Design, have an opportunity pipeline of over $100 million in commercial projects with more than $20 million in awarded backlog. According to the Rocky Mountain Institute, portfolio energy optimization is a $290 billion market in the United States driving deep financial savings and energy efficiency across the commercial sector.

Commercial buildings consume more than 35% of the generated electricity in the U.S. and are underperforming in energy efficiency at every level. These buildings waste energy, emit too much carbon, and are too costly for owners and occupants, but retrofits are not happening at the rate or scale needed.

In today’s real estate market, portfolio property owners own most commercial buildings. Yet most building efficiency work is focused on single buildings, thereby missing the distinct needs of this owner class which has very different needs than traditional owner-occupiers. The diverse nature of commercial buildings, combined with technology and performance uncertainty, make simple energy optimization initiatives – which could greatly reduce energy use and improve building value – financially unattractive, resulting in slow adoption rates. CIPI’s financial instruments and software breakdown this issue known as the “split incentive”, unlocking the majority of the addressable market.

Management Team

CIPI has in place a nationally recognized management team that has been active in the energy market since 2005.

Todd Michaels is President and CEO of CIPI and founder of Correlate. He formerly served as Vice President for Innovation at SunEdison and Senior Director Distributed Solar at NRG Energy. He founded Correlate in 2015 and has 16 years of experience in the energy industry. He graduated from Indiana University with a B.S. in Computer Information Systems.

Channing Chen is CFO at CIPI and Correlate Inc. and brings over 16 years of experience in the solar industry as a developer, financier, and business unit leader. He has held executive management roles at Solar Power Partners (acquired by NRG Energy), where he was a founding employee, SunEdison, and NRG Energy (NYSE: NRG). Most recently, Mr. Chen was founder and Managing Partner at Breakaway Energy Partners LLC – a distributed energy financing and market-making platform. To date, Mr. Chen and his teams have raised over $1.5 billion in financing across residential, commercial, and utility scale solar and energy storage projects representing over 400 MWs. He holds a B.A. in Environmental Chemistry from the University of California at San Diego and an MBA from the University of Southern California. He is also an advisor and early-stage investor to several startup companies in the renewable energy space.

David Bailey is Chief Revenue Officer of Correlate Inc. With over 15 years of executive sales, supply chain management, and energy efficiency experience, he is responsible for ensuring the success of the National Commercial Sales Unit across multiple regional project teams. Mr. Bailey created and launched the Transformation Services team while at Wesco for its multibillion-dollar Distributed Energy Resource division, formerly Westinghouse. His focus was on IoT-enabled efficiency and plant floor automation-based services. Before that, he spent several years in Global Account Sales Management, with GE Supply as a Program Manager, and is a Commercial Leadership Program graduate. Mr. Bailey received his B.S. in Mechanical Engineering from the University of Kentucky.

Jason Loyet is VP of Commercial Sales of Correlate Inc. He is a cleantech executive with over 20 years of experience leading high growth solar energy and software start-ups. Mr. Loyet is a U.S. Department of Energy SunShot Catalyst award winner for his work building the Solar Site Design technology platform. Before joining the solar energy industry in 2005, he founded and sold two software companies in the streaming media (GlobalStreams) and newspaper publishing (MyCapture) industries. Mr. Loyet currently serves as a Member of the Board of Directors for the Tennessee Solar Energy Industry Association (TenneSEIA).

Deke Welling is Head of Project Development and Fulfillment Services at Correlate Inc. He has over 19 years’ experience in the energy industry with an emphasis on renewables and energy efficiency over the past seven years. Prior to entering the renewables sector, Mr. Welling was the CEO of Welling Resources, an energy development company focused on the exploration of oil and natural gas reserves in the U.S. It was this experience that led him into the renewables sector and leading a charge for more sustainable resources. Additionally, Mr. Welling also served as the CEO of Circle L Solar Inc., a top 100 solar installer in the United States since 2016. Through his leadership, Circle L Solar experienced a growth rate of over 2,250% from 2016 to 2019, resulting in his company being listed on the Inc. 5000 list of the fastest growing private companies in the U.S. (Rank #176) and being named ‘Top Energy Company’ and ‘Entrepreneur of Year for the Energy Industry’ by the American Business Awards® in 2019 and again for ‘Entrepreneur of the Year’ in 2021.

Kevin Warren is Head of Construction and Development Engineering at Correlate Inc. He is a solar veteran with over 12 years of experience in the field. Prior to co-founding CLS, Mr. Warren was the owner of Beacon Consulting and has originated, consulted, designed and/or engineered over 122 MW of PV installations ranging from small commercial to utility scale projects throughout Texas, California, Colorado and North Carolina. He holds a Photovoltaic Technical Sales Professional Certification from the North American Board of Certified Energy Practitioners and certifications from Solar Energy International in PV Installation, PV Technical Sales, PV battery-based design, PV design and engineering, and PV operations and maintenance. Along with PV expertise, Mr. Warren is a LEED Green Building Associate, a certified building analyst from the Building Performance Institute, a Certified Renewable Energy Professional from the Association of Energy Engineers and holds a designation in High-Performance Sustainable Buildings from the BOMI Institute. He studied Electrical Engineering at the University of Texas at Arlington.

Tom Kunhardt is Director of Customer Success at Correlate. He previously held a similar position at Clean.Tech and was Corporate Trainer, Learning & Development, at NRG Energy. He has 15 years of experience in the solar and clean energy industries helping homeowners and businesses find solutions to their energy needs. He holds a bachelor’s degree from the University of Massachusetts.

Correlate Infrastructure Partners Inc. (OTCQB: CIPI), closed Monday's trading session at $1.08, even for the day. The average volume for the last 3 months is and the stock's 52-week low/high is $0.71/$3.25.

Recent News

Advanced Container Technologies Inc. (OTC: ACTX)

The QualityStocks Daily Newsletter would like to spotlight Advanced Container Technologies Inc. (OTC: ACTX).

There is an air of optimism at the turn of every new year, and the marijuana industry isn’t left behind. Cannabis business moguls are optimistic thatprofitable trends shall emerge for the industry’s fiscal year 2023.Last year saw some lows for the industry, from limited capitallending and investment to inflation and other factors. The new yearstarts with great hopes for the industry, and the market can lookfor several trends as the year progresses. Some 2023 trends to lookout for in the cannabis industry include the following:

Key market consolidation

The COVID-19 business boom created the analogy that the cannabisindustry cannot suffer a recession. However, Colorado and Washington are grappling with fallingprices as Michigan and Massachusetts markets are saturating. Thishas caused employee layoffs to cut costs. Incidentally, mergers and acquisitions havesignificantly gone down as capital lending for cannabisentrepreneurs has decreased. The new year is likely to see plentyof consolidation in the industry. This will continue moving forwardgiven that the cannabis industry stands as the largest in theUnited States with potential for increased growth. Even in Canadawhere some industrial action has taken place, unionization islikely to pick up pace. As these developments take shape, it wouldbe interesting to follow how ancillary companies such as Advanced Container Technologies Inc. (OTC: ACTX) fare in response to the direction the marijuana industry takes.

Advanced Container Technologies Inc. (OTC: ACTX) is in the business of selling and distributing self-contained, automated, indoor “micro-farms” called Grow Pods, along with related equipment and supplies. Additionally, the company designs and sells patented proprietary medical-grade plastic containers, known as the Medtainer®, that store and grind pharmaceuticals, herbs, teas and other solids or liquids.

ACTX is the leading distributor of Grow Pods. With a controlled environment, food and herbs can be grown without pesticides, harmful chemicals or risk of pathogen contamination, and with low energy consumption. Restaurants, grocery stores, non-profits, MSOs and entrepreneurs can use Grow Pods to ensure a fresh supply of ultra-clean produce year-round.

The company entered the Grow Pod business in October 2020 with its acquisition of all shares of Advanced Container Technologies Inc., a California corporation. As of February 28, 2022, ACTX is exploring the acquisition of the assets and the assumption of some or all of the liabilities of GP Solutions Inc., the developer and manufacturer of Grow Pods, for which ACTX is currently the sole U.S. distributor.

Because Grow Pods can be located almost anywhere, produce can be grown closer to the point of consumption and harvested at its peak, providing nutritious fruits and vegetables where needed. Indoor micro-farms, utilizing a practice known as vertical farming, have attracted the attention of governments and universities, which are now promoting vertical farming as a way to combat food insecurity and inequities.

The United States Department of Agriculture (USDA) has stated that vertical farming “is no longer a futuristic concept.” The department is enthusiastic about vertical farming, particularly those utilizing repurposed shipping containers, such as Grow Pods. Arizona State University reports that vertical farming reduces water use by 90 percent compared to conventional farming but produces 10 times the crop yield.

Products

Grow Pods

One of the company’s main business units is focused on selling advanced, self-contained hydroponic containers called Grow Pods. These unique and innovative automated systems are essentially micro-farms that can be placed virtually anywhere and, with their controlled and specially filtered environment, allow cultivation of a wide variety of crops, 365 days a year. The Grow Pod controlled environment offers major advantages for the production of high-value crops. The ability to grow year-round and the ability to cultivate in a smaller footprint using less water and power are some of the primary advantages of the system. Grow Pods offer constant temperature, humidity and airflow control, as well as automated watering and lighting schedules for optimal growth and minimal labor requirements, regardless of crop.

Containers

ACTX meets the needs of the pharmaceutical and medical markets, including the cannabis and hemp industries, with patented packaging systems. The company designs, customizes, brands and sells proprietary medical grade plastic containers that can store pharmaceuticals, herbs, teas and other solids or liquids, with a special built-in feature that can grind solids and shred herbs. The company’s flagship container product is the patented Medtainer®, a child resistant, medical-grade herb container and grinder that is water-tight, air-tight and smell proof. Packaging in the cannabis industry is critical, with numerous stringent regulations about how cannabis products must be packaged and labeled. ACTX also offers custom-branded, compliant vacuum seal bags and other retail container solutions.

Equipment and Supplies

ACTX markets and sells two principal products: Grow Pods, which are specially modified insulated shipping containers manufactured by GP Solutions Inc., in which plants, herbs and spices may be grown hydroponically in a controlled environment, and Medtainers®, which may be used to store pharmaceuticals, herbs, teas and other solids or liquids and can grind solids and shred herbs. The company also markets and sells various products related to Grow Pods and the Medtainer®, as well as providing private labeling and branding services for purchasers of Medtainers® and certain related products.

GP Solutions manufactures and sells other products, such as humidity controllers and LED lighting systems for vertical farming. The company’s specially designed lighting panels are programmed to emit the exact wavelength of light that each crop requires. The system has a daybreak-to-nightfall feature that gives plants the proper chromatic signals to grow rapidly and fruitfully. High efficiency LED light strips supply the crops with a red and blue light spectrum required for photosynthesis in the spectrum that plants need most.

Market Overview

The global vertical farming market is expected to reach $33.02 billion by 2030, according to a new report by Grand View Research. The market is forecast to expand at a CAGR of 25.5 percent from 2022 to 2030, according to Grand View. Escalating production of biopharmaceutical products, including cannabis, is anticipated to drive the market. The building-based segment of the market is expected to register a significant CAGR of 27.8 percent over the projected period. In addition, the climate control segment is expected to see high growth.

The global cannabis packaging market is expected to reach $14.34 billion by 2028, according to analysis by Reports and Data. The analysis forecasts 1,700 percent growth in cannabis users by the end of 2026, with packaging likely observing a whopping 26.42 percent growth in the forecast period. There are significant barriers to entry in the cannabis packaging market, giving an advantage to companies already established in the sector. These barriers include developing a thorough knowledge of the myriad regulations that govern cannabis packaging (which differ in each state), and child-resistance requirements.

Management Team

Douglas P. Heldoorn is the Founder and Chairman of Advanced Container Technologies Inc. He also holds the positions of President, CEO and COO at the company. Mr. Heldoorn has served on the Board of Directors since its inception in 2013. He has also previously held the position of Executive General Manager at Nissan Motor Corp.

Jeffory A. Carlson is CFO and Treasurer of ACTX. Mr. Carlson has also served as the company’s Corporate Controller since 2014.

Advanced Container Technologies Inc. (OTC: ACTX), closed Monday's trading session at $0.4, even for the day. The average volume for the last 3 months is and the stock's 52-week low/high is $0.2005/$1.42.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical innovator, is enrolling patients in theUnited States and Europe for its potentially pivotal globalclinical trial in humans for its lead drug candidate designed totreat glioblastoma multiforme (“GBM”), a common and one of the mostaggressive primary brain cancers. “The drug, Berubicin, is ananthracycline chemotherapy agent that apparently has the uniqueability to cross the blood-brain barrier to target tumors directly.The inability of anthracyclines to cross the blood-brain barrierhas been identified as a major obstacle in treating aggressivebrain tumors such as GBM and creates an opportunity for CNSPharmaceuticals,” a recent article reads. “Anthracyclines aredesigned to damage the DNA in cancer cells,” CEO John Climaco isquoted as saying. “Anthracyclines as a class of chemotherapy havebeen used for over 60 years to treat a variety of cancers,including breast, ovarian, lung, lymphoma and leukemia, and othermalignancies as well. However, historically, anthracyclines havenever been used to treat primary or metastatic brain cancersbecause scientists could not demonstrate that anthracyclines wereable to cross the blood-brain barrier and achieve significantlevels of activity in the brain. Berubicin may change thathistory.”

To view the full article, visit https://ibn.fm/ZoGTt

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Monday's trading session at $2.74, off by 5.5172%, on 20,637 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $2.05/$24.90.

Recent News

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV)

The QualityStocks Daily Newsletter would like to spotlight BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV).

The United States is currently facing a critical shortage of infectious disease experts. Infectious disease doctors, or IDs as they are commonly referred to in hospitals, are usuallytasked with diagnosing diseases and guiding hospital teams intreatment. This tends to involve collecting extensive and detailedmedical histories and reviewing past medical records thoroughly toidentify the root cause of a patient’s symptoms.Unsurprisingly, this infectious disease expert work requires atremendous amount of cognitive effort and plays a critical role inthe proper diagnosis and treatment of patients. It also requireskey qualifications, with ID doctors having to go through an extratwo to three years of specialized fellowship training on top of theusual three years of internal medicine residency training.Physician, researcher, epidemiologist and Vox reporter KerenLandman stated that while a career in infectious disease can bechallenging, it is also quite rewarding. Infectious disease expertsare a critical cog in the American healthcare system and a shortage of ID doctors can have devastating consequences,especially as the United States deals with the aftermath of thecoronavirus pandemic. This ID shortage in a way makes a strong casefor the efforts being undertaken by enterprises such as BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) to develop next-gen anti-infectious disease formulations so thatthe world doesn’t get caught in another large-scale outbreak thatbrings the global economy to its knees as was the case with therecent pandemic.

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses.

In collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences (MPG) and the University Medical Center Göttingen (UMG), both in Germany, BiondVax is developing a pipeline of innovative nanosized antibody (NanoAb) therapies addressing diseases underserved by current treatments and with large and growing markets, such as COVID-19, asthma and psoriasis.

NanoAbs, also known as VHH-antibodies or Nanobodies, are alpaca-derived nanosized antibodies that exhibit multiple significant competitive advantages over existing antibody therapies, including stability at high temperatures, superior binding affinity, more effective and convenient routes of administration and efficient production. BiondVax is uniquely positioned to advance nanosized antibody innovation from R&D through commercialization.

The company’s highly experienced and successful pharmaceutical industry leadership team includes former senior executives from Novartis, GSK and Bristol-Myers Squibb.

Since its founding, BiondVax has executed eight clinical trials, including a seven-country, 12,400-participant Phase 3 trial of a prior influenza vaccine candidate, and it built, owns and operates a 20,000 sq. ft. state-of-the-art GMP biologics manufacturing facility housing its laboratories, production facilities and offices.

Lead Candidate: Inhaled COVID-19 NanoAb

In December 2021, BiondVax signed definitive agreements with the Max Planck Society – parent organization of the Max Planck Institute for Multidisciplinary Sciences– and the UMG to enter a strategic collaboration for the development and commercialization of innovative COVID-19 NanoAbs.

The company is planning a rapid development path that leverages its expertise and capabilities in biological drug development and manufacturing. BiondVax anticipates preclinical proof-of-concept results for an inhaled COVID-19 NanoAb by the end of 2022, with initial Phase 1/2a human clinical trial results expected in 2023.

The intended inhaled mechanism of delivery of BiondVax’s COVID-19 NanoAb formulation may serve as a significant differentiator when compared to approved monoclonal antibodies, which are injected. Inhaled delivery has shown to be cheaper, more convenient and likely safer for patients and providers.

NanoAb Pipeline: Psoriasis, Asthma and More

The COVID-19 NanoAb development agreement is part of a broader five-year research collaboration agreement signed in March 2022 covering discovery, development and commercialization of NanoAbs for several other disease indications with large market medical needs, including asthma, psoriasis, macular degeneration and psoriatic arthritis.

BiondVax has an exclusive worldwide license for development and commercialization of COVID-19 NanoAbs and exclusive options for similar worldwide licenses for NanoAbs for the above mentioned additional large market disorders currently underserved by approved therapeutic antibodies.

Academic research teams from MPG and UMG have verified strong affinity by the new NanoAbs to their biological target molecules and high thermostability. They have also demonstrated strong neutralization by several NanoAb candidates of their respective target molecules. Neutralization studies of the other NanoAbs are expected to begin later in 2022.

Based on the promising results, BiondVax will focus development efforts beginning with the following NanoAbs:

  • NanoAbs targeting IL-17 as drug candidates for the potential treatment of psoriasis and psoriatic arthritis
  • NanoAbs targeting IL-13 and NanoAbs targeting TSLP as drug candidates for the potential treatment of asthma

These are conditions for which the antibody target is validated by existing treatments and the mechanism of action is well understood. Both represent large medical needs and growing markets. BiondVax anticipates preclinical proof-of-concept for at least one of these NanoAbs in 2023. This is in addition to the aforementioned human clinical Phase 1/2a for the inhaled COVID-19 NanoAb therapy, which is also anticipated in 2023.

Market Opportunity

COVID-19 treatment, target of the company’s lead NanoAb therapy candidate, had an estimated market size of $22 billion in 2021.

Future BiondVax drug candidates will target conditions with large markets growing at attractive CAGRs.

The global asthma treatment market was valued at $18.08 billion in 2019 and is projected to reach $26.01 billion by 2027, exhibiting a CAGR of 4.5% during the forecast period, according to Fortune Business Insights. The research firm predicts that the global psoriasis treatment market will grow from $26.37 billion in 2022 to $47.24 billion by 2029, exhibiting a CAGR of 8.7% over the forecast period.

Management Team

Amir Reichman is BiondVax’s CEO. He previously was Head of Global Vaccines Engineering Core Technologies at GSK Vaccines in Belgium. Prior to that, he held leadership roles at Novartis Vaccines’ Global Vaccines Supply Chain Management organization. He was the first employee of NeuroDerm Ltd., a company focused on transdermal drug delivery, and served as Chief Engineer and Senior Scientist until his departure in 2009. He earned a M.Sc. in Biotechnology Engineering from Ben-Gurion University and an MBA in Finance and Health Care Management from the University of Pennsylvania’s Wharton School.

Tamar Ben-Yedidia, Ph.D., is Chief Science Officer at BiondVax. She has more than 30 years of experience in immunology, with specific expertise in the development of vaccines. She began her career with Biotechnology General Ltd., working on development of a recombinant Hepatitis-B vaccine. She later joined the Weizmann Institute of Science, working on the design of a peptide-based vaccine against several pathogens. She is widely published, with numerous refereed articles and invited reviews in various scientific journals. She received her Ph.D. from the Weizmann Institute.

Elad Mark is COO at BiondVax. He has over 15 years of biotechnology industry experience encompassing diverse project stages including feasibility studies, conceptual and detailed design, commissioning, qualification and process validation. Prior to joining BiondVax, he led Novartis’s $800 million investment in a biologics facility in Singapore. With Biopharmax and Antero, both global pharmaceutical engineering companies, he successfully led projects in Israel, China and Singapore. He holds a BSc. in Engineering from the Afeka Tel Aviv Academic College of Engineering and an MBA from the Open University of Israel.

Uri Ben-Or is CFO at BiondVax. He has served as CFO with public life science companies traded on the TASE, OTC and Nasdaq. Ben-Or provides his services to BiondVax through CFO Direct, a company he founded and for which he serves as CEO. He served as the VP of Finance of Glycominds, a leading biotechnology company, and as CFO of a spin-off from Telrad Networks. He also served as a Corporate Controller at Menorah Capital Markets and as an Auditor at PWC. He holds a B.A. in Business from the College of Administration, an MBA from Bar-Ilan University, and is a CPA.

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), closed Monday's trading session at $2.69, off by 10.3333%, on 752,169 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $2.54/$22.90.

Recent News

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

Lexaria, a global innovator in drug delivery platforms, hasdeveloped the patented DehydraTECH(TM) platform technology, whichhas been shown to increase the bio-absorption of variousfat-soluble active molecules and drugs

In a recently completed study, Lexaria showed thatDehydraTECH-processed CBD had exceptional safety and tolerabilityprofile in addition to resulting in a statistically significantlowering of 24-hour ambulatory blood pressure

The company also reported that it had demonstrated superior CBDblood absorption levels in its HYPER-H21-4 study fromDehydraTECH-CBD relative to those of published comparators

At the lowest (3.38 mg/kg) and highest (4.46 mg/kg) dose levelstested, DehydraTECH-CBD resulted in 45.8% and 133.4% higher averageblood plasma levels, respectively, than the figure reported when ahigher (5 mg/kg) dose level of non-Lexaria, pharmaceutical-gradeCBD was administered

Global innovator Lexaria Bioscience (NASDAQ: LEXX) has developed a proprietary platform technology that is capable ofdelivering certain drug molecules more effectively into the humanbody than their generic forms. That, CEO Chris Bunka contends (https://cnw.fm/FEXdl), allows for various efficiencies and decreases in adverse sideeffects.

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Monday's trading session at $2.6027, off by 3.2454%, on 16,977 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.80/$4.94.

Recent News

Knightscope, Inc. (NASDAQ: KSCP)

The QualityStocks Daily Newsletter would like to spotlight Knightscope, Inc. (NASDAQ: KSCP).

Knightscope (NASDAQ: KSCP), a developer of advanced physical security technologies focused onenhancing U.S. security operations, announced that it has secured four new contracts in a successful start of2023. Under the contracts, Knightscope will deploy three K5Autonomous Security Robots (“ASRs”) and five K1 Blue Light Towers.The deployment locations include an existing Knightscope channelpartner’s regional corporate office in Jacksonville, Florida, anIllinois-based casino, as well as the parking lot of an apartmentcomplex for a well-known learning institution. A teaching hospitalhas also purchased five K1 Blue Light Towers to improvecommunications and safety on its New York medical campus. Inaddition, Knightscope today announced its planned path to profitability. Having recently committed toworking to achieve profitability within 24 months, the company’sannouncement marks the implementation of initial actions defined inits plan to achieve this important milestone. The announcementreads, “Knightscope continues to work to accelerate its top-linerevenue growth through new sales contracts, expansion with existingclients, contract renewals, and increased engagement through itsreseller program. Additionally, the company is progressing well indelivering on its multimillion dollar backlog of new orders as manysupply chain issues have subsided.” To view the full pressreleases, visit https://ibn.fm/ZPw2e and https://ibn.fm/b0FMM

Knightscope, Inc. (NASDAQ: KSCP), founded in 2013 and based in Mountain View, California, is a leader in the development of autonomous security capabilities targeting to disrupt the $500 billion security industry. Knightscope’s technology uniquely combines self-driving technology, robotics, artificial intelligence and electric vehicles.

Knightscope designs and builds Autonomous Security Robots (ASRs) that provide 24/7/365 security to the places you live, work, visit and study. The company’s client list covers public institutions and commercial business operations, including multiple Fortune 1000 companies to date. These ASRs have been proven to enhance safety at hospitals, logistics facilities, manufacturing plants, schools and corporations. ASRs act as highly cost-effective complementary systems to traditional security and law enforcement officials, providing an additional advantage by continuing to offer uninterrupted patrolling capabilities across the country.

The company’s ASRs have assisted in the arrest of suspects involved in crimes ranging from armed robbery to hit-and-runs. Their machine-embedded thermal scanning capability even aided in preventing the breakout of a major fire. You can learn more about the crime fighting wins at www.knightscope.com/crime

The company has achieved several milestones since its creation in 2013, including:

  • Establishing itself in a 15,000-square-foot facility located in Mountain View, California, in the heart of Silicon Valley, where Knightscope designs, engineers and builds its technology (Made in the USA)
  • Operating for more than 1 million hours in the field and securing contracts across five time zones, from Hawaii to Rhode Island
  • Raising over $100 million since inception to build its technology from scratch and generating over $13 million in lifetime revenue, validating both the market opportunity and the technology

Growth Capital & Proposed Nasdaq Listing

With backing from more than 28,000 investors and four major corporations and over $100 million raised since inception, Knightscope is poised to be an industry leader in the future of public safety and security.

On December 1, 2021, Knightscope announced the commencement of an offering of up to $40 million of its Class A common stock, with shares to be listed immediately following closing on the Nasdaq Global Market under the ticker symbol ‘KSCP’. The offering is for up to 4 million shares priced at $10 per share. Learn more at www.knightscope.com/investors

Company Mission – Reimagining Public Safety

Knightscope’s long-term vision has an eye on the greater good. The company’s mission is to make the United States of America the safest nation in the world while supporting the 2+ million law enforcement and security professionals across the country.

Crime has an estimated negative economic impact in excess of $2 trillion annually. As crime is reduced, positive impacts will likely be realized across several aspects of society, including housing, financial markets, insurance, municipal budgets, local business and safety in general.

Knightscope CEO William Santana Li was interviewed by Kevin O’Leary, more commonly known as Shark Tank’s Mr. Wonderful. When asked to explain how the benefits provided by the ASRs outrank a human doing the same job, Li said, “First, just the simple presence of a physical deterrent causes criminal behavior to change. Second, the machines are self-driving cars that patrol all around and recharge themselves. They also generate 90 terabytes of data per year. No human would ever be able to process that. The robots are intended to be eyes and ears for the humans, not a one-to-one replacement.”

The Knightscope solution to reduce crime combines the physical presence of ASRs, sometimes referred to as proprietary Autonomous Data Machines, with real-time onsite data collection and analysis. The ASRs are fitted with eye-level 360° cameras, thermal scanning, public address announcements and various other features that work in tandem with humans to provide law enforcement officers and security guards unprecedented situational awareness.

Those 90 terabytes of data are then formatted in a useable way, so law enforcement can leverage that information and execute their responsibilities more effectively.

Public Safety Innovation

The company’s recurring revenue business model is set up to mimic the recurring societal problem of crime, and it takes into consideration the fact that innovation in the security and public safety industry has been stagnant for decades. Because the traditional practices of the sector have remained unchanged for years, automation has potential to drive substantial cost savings – and significant improvement in capabilities.

Human security guards are one of both the largest expenses and the largest liabilities for companies. Knightscope’s robots are offered at an effective price of $3 to $9 per hour, compared with approximately $85 for an armed off-duty law enforcement officer and $15 to $35 for an unarmed security guard.

This innovation has the potential to drive considerable cost savings. Based on these estimates, manufacturing costs can be recovered as soon as the first year of operation.

Product Offerings

The company has nine patents and a framework of unique intellectual property. Knightscope currently offers a K1 stationary machine, a K3 indoor machine and a K5 outdoor machine. A K7 multi-terrain four-wheel version is in development.

The ASRs autonomously patrol client sites without the need for remote control, providing a visible, force multiplying, physical security presence to help protect assets, monitor changes in the area and deter crime. The data is accessible through the Knightscope Security Operations Center (KSOC), an intuitive, browser-based interface that enables security professionals to review events generated by the ASRs providing effectively ‘mobile smart eyes and ears’. Learn more at www.knightscope.com/ksoc

The ASRs and the related technologies were developed ground up by the company and are Made in the USA.

The Robot Roadshow

Knightscope has created the ultimate hybrid physical and virtual event, bringing its Autonomous Security Robot technologies to cities across the country for interactive and in-person demonstrations.

Each roadshow landing is hosted virtually by a Knightscope expert, and visitors can interact directly with each of the company’s ASRs and see the Knightscope Security Operations Center (KSOC) user interface in action. Learn more at www.knightscope.com/roadshow

Management Team

Chief Executive Officer William Santana Li is a veteran entrepreneur, a former executive at Ford Motor Company and the founder of GreenLeaf, a company that grew to be the world’s second-largest automotive recycler and is now part of LKQ Corporation (NASDAQ: LKQ).

Chief Client Officer Stacy Dean Stephens brings his experience as a former Dallas law enforcement officer, as well as his skills as a seasoned entrepreneur, to assist on the client acquisition side.

Chief Intelligence Officer Mercedes Soria is an award-winning technologist and former Deloitte software engineer.

Chief Design Officer Aaron Lehnhardt brings over two decades of two- and three-dimensional product and industrial design in modeling and VR to the table, on top of his experience as a senior designer at Ford Motor Company.

Chief Financial Officer Mallorie Burke is a seasoned financial executive and strategic advisor for both private and publicly traded technology companies with a successful track record of mergers & acquisitions, corporate growth and exit strategies, including public listings.

General Counsel Peter Weinberg leverages 30 years of diverse corporate counsel experience, spanning from startups to well-established companies, private and public. He has significant experience training personnel at all levels in critical areas to improve corporate compliance and productivity.

Knightscope, Inc. (NASDAQ: KSCP), closed Monday's trading session at $1.82, off by 8.5427%, on 297,718 volume. The average volume for the last 3 months is 294,591 and the stock's 52-week low/high is $1.35/$27.50.

Recent News

Flora Growth Corp. (NASDAQ: FLGC)

The QualityStocks Daily Newsletter would like to spotlight Flora Growth Corp. (NASDAQ: FLGC).

Flora Growth Corp. (NASDAQ: FLGC), a cannabis cultivator and global distributor, is a rapidlygrowing house of brands building customer bases and distributionchannels across international lines as it aims to distinguishitself within a highly competitive arena. “Much of Flora Growth’sstrength lies in its licensed cultivation, extraction and isolationfacility located in northern Colombia’s fertile climate, where anexperienced labor force is helping the nation emerge from decadesof drug war illicit trade into a recognized and regulated market,”a recent article reads. “From its 247 acres of growing fields, thecompany’s harvests move into a production pipeline that includes aflower and derivatives production lab situated within thecultivation camp, as well as a topical, capsules and dietarysupplements lab in Colombia’s capital and a third lab in the UnitedStates, where CBD ingestible, tinctures and gummies are made. Afourth state-of-the-art lab being built in Colombia’s capital isbeing designed to formulate custom and proprietary pharmaceuticalsthat will be sold and used in Colombia. The life sciences lab isexpected to open by the end of this year with eight registeredpharmaceutical grade formulas that target specific ailments such asinsomnia, epilepsy and anxiety.”

To view the full article, visit https://cnw.fm/QWUen

Flora Growth Corp. (NASDAQ: FLGC) is an internationally focused cannabis brand builder that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions, including cosmetics, hemp textiles, and food and beverage. Flora Growth operates one of the largest outdoor cultivation facilities in the world with an aim of marketing a higher-quality premium product at below-market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, the company creates premium products that help consumers restore and thrive.

Flora Growth completed the first traditional cannabis IPO on Nasdaq in May 2021. Although currently headquartered in Toronto, Ontario, with plans to relocate its head office to Miami, Florida, the company’s base of operations is in Colombia, where it has built an extensive distribution network that includes Colombia’s largest distributors.

Currently, Flora Growth is organically growing market share for its existing brand portfolio (pharmaceuticals, textiles, cosmetics, and food & beverage) while seeking revenue-generating acquisitions that offer an accretive distribution network to amplify revenue growth.

Existing Brand & Product Portfolio

Flora Growth’s portfolio spans a number of verticals – each with a thoughtful brand designed to resonate with its intended end consumer. In line with the company’s mission, each brand prioritizes natural ingredients and value-chain sustainability.

Flora Lab S.A.S

Flora Lab is the company’s GMP certified manufacturing and R&D center focused on producing pharmaceuticals, cosmetics, and nutraceuticals for domestic and international markets. Its offerings include product lines that are private label, white-label, and custom formulas.

Through Flora Lab, Flora Growth has relationships with 1,500+ distribution channels, manufactures 63+ OTC products registered with INVIMA (Colombia National Food and Drug Surveillance Institute), and holds multiple GMP certifications enabling international export in an effort to leverage Flora Lab’s capacity to produce a wide range of CBD-infused products.

Flora Beauty

Flora Beauty is the company’s CBD beauty and cosmetics division founded by fashion and beauty industry icon Paulina Vega. Its current offerings include two CBD skincare brands targeting the U.S. and Latin American markets – MIND NATURALS and AWE. These lines exemplify Flora Growth’s socially conscious approach to business.

Currently, Flora Beauty products are offered globally through e-commerce, as well as through Falabella’s 111 retail locations across Latin America. The company is in negotiations with major department stores to launch the line in the U.S. and is also exploring opportunities in the U.K. and other European markets.

KASA Wholefoods

KASA Wholefoods is a Colombian manufacturer of food and beverages leveraging responsibly sourced exotic fruits from the Amazon. KASA has a $10 million+ distribution agreement with Tropi, Colombia’s largest food distributor, which has 130,000+ distribution points across the country.

Mambe, KASA’s leading brand, is already offered through over 980 distribution points across Colombia. Flora Growth expects this network to grow to over 1,200 distribution points in 2021, including one of Colombia’s largest coffee chains, Tostao Café & Pan.

Hemp Textiles & Co.

Through its Hemp Textiles division, Flora Growth intends to utilize its large land package and cultivation infrastructure to capture market share in the rapidly growing hemp industrials segment.

The company’s first brand through this division, Stardog Loungewear, offers a line of comfortable loungewear made from natural, organic materials. Stardog has been distributing globally through e-commerce and brick and mortar channels in Bogota since fall 2020, and the company intends to open U.S. brick and mortar locations in 2021.

Accretive M&A

Flora Growth is targeting transactions to complete the supply chain via key infrastructure to enhance its global distribution with the aim to compete on low-cost, high-quality inputs paired with premium brands that create business lines with robust margins.

To date, Flora has announced two major transactions.

Koch & Gsell (Acquisition)

  • Amplify CPG portfolio’s revenue growth through leading brand, Heimat, currently with TTM revenues of $7.6 million.
  • Leverage Koch &Gsell’s distribution network of 2,500+ stores to introduce Flora to the Swiss, European and Asian markets.
  • Bring patented hemp cigarette manufacturing technology into new markets utilizing Flora’s high-quality cannabis.

Hoshi International (Investment)

  • Equity Investment of €2 million into Hoshi to establish Flora as a preferred supplier to two EU processing facilities.
  • Opens gateway for Flora Growth’s cannabis through international distribution agreements in the EU and U.K.
  • Hoshi’s experienced team and increased access to the EU cannabis market to serve as a catalyst for revenue growth.

Cultivation

Key to Flora Growth’s expansion efforts is its cultivation strategy. The company’s Cosechemos farm, located in Bucaramanga, Colombia, is currently licensed to cultivate 247 acres of cannabis. Through three successful pilot crop plantings, the location has demonstrated a production cost of just $0.06/gram. For comparison, the average cost of North American cannabis (based on 2019 figures from Aphria, Tilray, Sundial, and Aurora) equates to roughly $1.89/gram.
Flora Growth is uniquely positioned to capitalize on Colombia’s favorable growing conditions, low-cost infrastructure, and affordable local workforce as it looks to ramp up its cultivation efforts moving forward.

Leadership Team

Bernard Wilson is the Chairman of Flora Growth. A senior financial professional, Dr. Wilson is the former Vice-Chairman of PricewaterhouseCoopers LLP and is the Chairman of the Founders Board of the Institute of Corporate Directors. He has also served as Chairman of the Canadian Chamber of Commerce; Chairman of the International Chamber of Commerce – Canada; and Member of the Canada/U.S. Trade Committee. Dr. Wilson draws on this experience to ensure Flora Growth adheres to effective corporate governance practices.

Luis Merchan is the company’s President and CEO. He is a proven executive with over a decade of experience in enterprise sales management, corporate strategy, merchandising and expense management, and customer experience. Mr. Merchan previously served as Macy’s Inc.’s Vice President of Workforce Strategy and Operations, where he managed the enterprise’s multi-billion-dollar P&L expense line for the entire 540 store portfolio. Throughout his tenure at Macy’s, he led various sales and marketing initiatives, including the B2B corporate sales team that was responsible for $160 million in annual revenue. Mr. Merchan obtained his Bachelor of Industrial Engineering from Pontifical Xaverian University in Bogota, Colombia, and his MBA from McNeese State University. He also holds a Graduate Certificate in Marketing Management from Harvard.

Juan Manuel Galan is a Strategic Advisor to the Flora Growth management team. Mr. Galan currently serves as a senior consultant to The World Bank. He is a politician and former senator of Colombia, serving three terms from 2006 to 2018 as a member of the Colombian Liberal Party. He is also a former professor at the University of Rosario and holds more than 20 years of journalistic, academic, governmental and parliamentary experience. During his time as a senator, Mr. Galan was a key leader, with 29 bills and 27 debates on political control, and 17 laws to his name. The most relevant of those laws was authoring the medical cannabis law that resulted in the legalization of medical cannabis in Colombia.

Stan Bharti is a Director of Flora Growth. Mr. Bharti currently serves as Executive Chairman of Forbes & Manhattan. He has more than 30 years of professional experience in business, finance, markets, operations and more, with a focus on the resource and technology sectors. To date, Mr. Bharti has amassed over $3 billion worth of investment capital for the companies with which he has worked and their shareholders. He is a Professional Mining Engineer and holds a master’s degree in engineering from Moscow, Russia, and University of London, England.

Javier Franco is the company’s VP of Agriculture. Mr. Franco is a master horticulturist with more than 25 years of experience in the design, implementation, and management of cultivation and propagation facilities of more than 30 species of cut flowers in Latin America. He completed his agricultural studies at Zamorano University in Honduras and later at an International Exchange Program at Ohio State University. Mr. Franco has directed technical, commercial, and research groups in the cut flower, fruit and vegetable markets in Latin America and has participated in the commercial development of new technologies applied in agribusiness. He has also led the agri-management of organic crops and certifications of Good Agricultural Practices.

Flora Growth Corp. (FLGC), closed Monday's trading session at $0.2444, off by 4.1569%, on 675,699 volume. The average volume for the last 3 months is 666,889 and the stock's 52-week low/high is $0.21/$2.38.

Recent News

MetAlert Inc. (OTC: MLRT)

The QualityStocks Daily Newsletter would like to spotlight MetAlert Inc. (OTC: MLRT).

MetAlert (OTC: MLRT), a pioneer in location-sensitive, health-monitoring devices andwearable technology products for remote patient monitoring,spotlighted in a recent Q&A analyst report released by LudlowResearch. In the article, MLRT representations respond toquestions, providing an overview of the company and discussingspecific topics investors and shareholders might be interested in.The report delved into the company’s recent restructuring, namechange and ticker symbol change, with the company stating that “wewaited patiently to do this until we had a clean balance sheet andwere prepared to take the company to the next level.” The reportnoted that the company recognized a tremendous opportunity, but theprevious name, stock price and market cap didn’t reflect thecompany’s vision, mission and direction. The report also touched onsupply chain issues, order fulfillment, a potential uplisting andbecoming a reseller of RoomMate, a remote monitoring device totrack people at home or assisted-living facilities. The companyalso responded to concerns about how a possible recession mightimpact the company. “We don’t burn a lot of cash,” the companystated in the analyst brief. “Besides keeping our expenses to aminimum, not spending money on lavish things, our main countermeasure is thanks to our board and management team, which take muchlower than industry standard wages, they also defer approximately athird of their cash compensation. If you look at our balance sheet,just about all our debt, is years of deferred cash comp. Talk aboutkeeping management motivated, we all know we need to work very hardin order to eventually get paid. Between not spending a lot, notsubordinating a heavy debt load, along with providing high marginmust have products and services, is how we plan to face a possibleeconomic slowdown. Remember our products are not luxury items thatpeople turn off when the economy slows down, our products areessential to our users, their loved ones, and caregivers.”

To view the full article, visit https://ibn.fm/W9yoy

MetAlert Inc. (OTC: MLRT) is a pioneer in location sensitive health monitoring devices (estimated $47 billion industry in 2021) and wearable technology products (industry forecast to reach $174 billion by 2030).

With over 20 years of experience and an extensive patent portfolio (30+), MetAlert is a leader for consumers/patients afflicted with Alzheimer’s, dementia, and autism (ADA). This market represents approximately 2.9% of the world’s population (approximately 34 million people in 24 developed countries). Due to specific behaviors (problems with memory, adversity to wearing unknown items, etc.) of consumers/patients in this market segment, traditional products, such as an iPhone or Fitbit, are not a practical solution. This has created a significant market with very few competitors for MetAlert.

MetAlert and its subsidiaries are engaged in designing, developing, manufacturing, distributing, and selling products and services in GPS/BLE wearable technology, personal location, wandering assistive technology, and health data collection and monitoring. The company offers a global end-to-end hardware, software, and connectivity solution, in addition to developing two-way tracking technologies, which seamlessly integrate with consumer products and enterprise applications.

Using its award-winning, patented GPS SmartSole® as a hub for collecting and transmitting data to the cloud in real-time, MetAlert is expanding its value proposition to consumers and increasing its revenue per user (RPU) while creating the largest database of health statistics for ADA consumers/patients. MetAlert generates revenue from product sales, recurring subscriptions, intellectual property (IP) licensing, and professional services. The company has international distributors servicing customers in over 35 countries and is an approved U.S. military government contractor. Its customers include public health authorities and municipalities, emergency and law enforcement, private schools, assisted living facilities, NGOs, small business enterprises, senior care homes and consumers.

The company is headquartered in Los Angeles, California, with a sales office in London, England, and distributors across the globe.

Products

  • GPS SmartSoles® HUB (launched Q4 2022) is a GPS/BLE-equipped insole that allows remote monitoring, data collection, and encrypted data transmission to the cloud.
    • Telehealth (available Q4 2022) allows access remotely to doctors and other health professionals on an as-needed basis. This service will also function as the prescribing doctor once Medicare reimbursement codes are established.
    • Concierge (available Q4 2022) provides 24/7/365 enhanced emergency response that coordinates with all relevant parties to quickly detect false alarms and escalate response as needed.
    • Bluetooth Enabled Devices (available Q1 2023) include third-party devices that collect vitals and other health data and connect with the GPS Smartsoles® HUB.
    • Artificial Intelligence (available Q1 2023) software will evaluate the Teradata of health information identifying trends and respond to preestablished alert thresholds.
  • Take-Along Tracker is a small GPS tracking device – less than three inches long – that works with 4G cellular service and will have the same “HUB” functionality as the GPS Smartsoles®. This versatile and affordable mini tracker boasts super long battery life, with up to 14 days of operation per charge.
  • RoomMate™ is a wall-mounted alert system that detects and alerts caregivers about patient behavior that could lead to falls and injuries. The system features 3D infrared and wall-mounted sensors, eliminating the need for any other physical installation or wearables. RoomMate™ offers patient privacy by design. Images are not stored, but all actions are logged. It’s a unique solution for looking after patients without intruding on their personal space.

Market Outlook

According to Grand View Research (Patient Monitoring Devices Market Size & Share Report, 2030), the global patient monitoring devices market size was valued at $47.0 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 7.8% from 2022 to 2030. The expansion of the industry can be attributed to the rise in demand for monitoring devices used to measure, distribute, record, and display a variety of biometric data, including blood pressure, temperature, and blood oxygen saturation level.

The growing number of chronic disorders, such as diabetes, stroke, and kidney disease, are driving the demand for patient monitoring devices. For instance, according to the World Health Organization (WHO), about 422 million people globally have diabetes. Likewise, the number of asthma and chronic obstructive pulmonary disease patients (COPD) is increasing rapidly.

According to the WHO, around 235 million people suffer from asthma. As a result, peak flow meters, which are used to gauge respiration rate, are increasingly used. The market for patient monitoring devices is driven by the simplicity with which it is handled, transported, and remotely accessible. Major market players are engaging in a variety of tactics to expand the industry, including partnerships, cooperation, innovation, launches, and mergers.

During the COVID-19 outbreak, social segregation and quarantining procedures were put into place worldwide. Many people avoided regular hospital visits as a result. Many people now need routine home temperature and oxygen level monitoring to maintain track of their health, thereby demanding monitoring devices at home.

Various government programs are supporting the pandemic outbreak. The FDA has granted Emergency Use Authorizations (EUAs) for a few wearables and patient monitoring devices to improve access to medicines, monitor patients more closely, and lessen the risk of SARS-CoV-2 exposure to medical professionals during the COVID-19 pandemic.

The growing popularity of wearable and remote patient monitoring devices is another factor fueling the market’s expansion. By fusing clinical symptomology with vital indicators, wearable technology helps in the diagnosis of many chronic diseases. Thus, there has been a dramatic rise in the usage of wearable technology to combat COVID-19.

The wearable medical device market is anticipated to reach $174.48 Billion by 2030, expanding at a 27.1% CAGR during the forecast period (2022-2030), according to Market Research Future.

MetAlert identifies the total addressable market for its wearable patient monitoring tech for those with Alzheimer’s, dementia, and autism at more than 34 million potential patients in North America, Europe, South Africa, and Asia.

Management Team

Patrick E. Bertagna is Founder, CEO and Chairman at MetAlert. He began his career in apparel sales in 1983 and was promoted to national sales manager within two years. In 1986, he founded his first company importing apparel from Europe and selling to U.S. retailers from JCPenney to Neiman Marcus. He has founded several technology and apparel companies, including MetAlert in 2002, which he took public in 2008. He attended Cal State University Northridge with a business major and a psychology minor.

Louis Rosenbaum is COO of MetAlert. He co-founded Global Trek Xploration and was an initial investor in MetAlert. He has successfully started companies in multiple industries, including apparel, environmental services, and the music industry, achieving annual revenues in the multi-millions of dollars. He previously was president of Elements, a women’s apparel company, and of Advanced Environmental Services.

Alex McKean is CFO at MetAlert. He is also the CFO of Encore Brands Inc., a position he has held since 2009. He has held positions as Controller and VP of Finance at 24:7 Film and InternetStudios.com, Director of FP&A/SVP at Franchise Mortgage Acceptance Company, Corporate Accounting Manager/Treasurer of Polygram Filmed Entertainment and Assistant Treasurer/Controller for State Street Bank. He holds an International MBA from Thunderbird School of Global Management and undergraduate degrees in business and political science from Trinity University.

MetAlert Inc. (OTC: MLRT), closed Monday's trading session at $0.24, off by 17.2414%, on 13,109 volume. The average volume for the last 3 months is 13,109 and the stock's 52-week low/high is $0.06/$1.00.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.